

Review | Received 27 June 2024; Accepted 30 August 2024; Published date  
<https://doi.org/10.55092/bm20240008>

# Challenges in osteochondral repair– a critical review

Jalaja Aswathy<sup>1,2</sup>, Josna Joseph<sup>3</sup> and Annie Abraham<sup>1,\*</sup>

<sup>1</sup> Department of Biochemistry, University of Kerala, Kariavattom, Thiruvananthapuram 695581, India

<sup>2</sup> Phytochemistry and phytopharmacology Division, KSCSTE-Jawaharlal Nehru Tropical Botanic Garden and Research Institute, India

<sup>3</sup> Dept. Clinical Immunology & Rheumatology, Christian Medical College, Vellore, Tamil Nadu 632004, India

\* Correspondence author; E-mail: [annieab@keralauniversity.ac.in](mailto:annieab@keralauniversity.ac.in).

**Abstract:** Osteochondral (OC) tissue repair is a significant challenge in managing osteoarthritis patients, as osteoarthritis (OA) progressively deteriorates both cartilage and subchondral bone, reducing quality of life. Restoring OC regions with complete structural and functional recovery is crucial. Despite availability of various OC constructs for OA joint repair, ensuring their stability and bone support remains problematic. The primary obstacle in attaining favourable patient outcome is designing constructs tailored to individual needs. This critical review addresses the various challenges in OC tissue repair, including (i) anatomical complexities, (ii) biological approaches to restoring the OC interface, and material selection, (iii) cell sources for reconstruction, and (iv) recreating a coordinated microenvironment. The findings arising out of this introspection, underscore the need for innovative strategies to overcome these OC tissue repair limitations, aiming at restoring OC unit structure and function in OA patients.

**Keywords:** osteochondral unit; osteoarthritis; stem cells; osteochondral construct; scaffolds

## 1. Introduction

Osteochondral (OC) repair in osteoarthritis is the therapeutic strategy to restore damaged joint surfaces and underlying bone in individuals suffering from osteoarthritis (OA). OA is a chronic degenerative disease affecting the elderly, especially women [1]. The pathological condition of OA is characteristically progressive by cartilage breakdown, the collapse of the subchondral bone, fibrosis, hypertrophy of the synovial tissue and degeneration of menisci, and finally, osteophyte formation [2,3]. This osteophyte formation, followed by softening, fibrillation, and abrasion of the cartilage lead to the denudation of underlying bone and OC



Copyright©2024 by the authors. Published by ELSP. This work is licensed under Creative Commons Attribution 4.0 International License, which permits unrestricted use, distribution, and reproduction in any medium provided the original work is properly cited.

defects. The reconstruction of OC defects in OA patients is challenging as anatomical restrictions, pathological limitations, host response factors, and translational challenges exist. According to the data provided by the World Health Organization (WHO), OA remains a significant global health concern, affecting 528 million individuals ie, about 6.5% are suffering with OA around the world. WHO's statistical findings underscore the widespread prevalence of OA, and the average age of onset is above 55, and 60% of them are women [4]. Age-standardized prevalence rates (ASRs) show that the global rate of osteoarthritis (OA) is 6.34%, with an annual rise of 0.12% [5]. The prevalence of OA in rural and urban India is estimated to be 3.9% and 5.5%, respectively [6]. There is an increased concern about this disease since an estimated 18% of post-menopausal women worldwide and 22–39% of the Indian population suffer from OA [7,8]. Previously, OA was considered as a joint disorder; later, studies revealed that it affects the whole joint organ [9]. To address this clinically, various approaches have been developed to promote repair *via* replacement or regeneration of the OC unit. These strategies involve microfracture, mosaicplasty, autologous chondrocyte implantation, tissue replacement, and tissue engineering approaches using biomaterials and stem cells. These interventions aim to enhance cartilage healing, reduce pain, improve joint function, and potentially slow down disease progression. OC repair promises to improve the quality of life for affected individuals, but further research is needed to optimise this technology to understand its long-term efficacy and safety. Therefore, this review offers insights into various challenges in OC repair, existing sophisticated technologies, ongoing technical advancement, and clinical trials in OC tissue restoration.


## 2. Anatomical challenges

### 2.1. OC unit/OC tissue anatomy

OC tissue is arranged as a discrete zone, and the level of zonal discrimination accounts for Extra Cellular Matrix (ECM) composition, collagen orientation, and chondrocyte phenotype, morphology, organization, and number [10]. The height of the OC unit varies significantly from one individual to another and this variability is due to the different knee joint size, shape, biomechanics, *etc.* The average height of OC tissue ranges from about 3 mm, and 90% of it is constituted by cartilage the remaining 5% by calcified cartilage zone, and the other 5% by subchondral bone plate respectively [11]. Unlike most tissues, articular cartilage is devoid of blood vessels, nerve innervation, and lymphatics [12–14] and the movement of nutrients and the excretion of waste is primarily *via* diffusion to-and-from neighbouring tissues. This exchange is possible only through synovial fluid, a viscous liquid that bathes the cartilage surfaces within joints [15–17]. In addition to the synovial fluid, proteoglycans and glycoproteins like lubricin [18] in the articular cartilage that lines up the bone surface in the OC unit act as flexible connective tissue in the synovial joints throughout the body, responsible for movement with almost zero friction [18–21]. The delicate balance of nutrient exchange is crucial for sustaining cartilage's unique structure and function, maintaining optimal synovial fluid composition and circulation for cushioning joints, and enabling smooth movement. While considering these facts another significant challenge for OC

damage healing is the lack of blood vessels for delivering nutrients, oxygen, and immune cells necessary for the repair process. Also repair of injury of a perichondrium-like fibrous membrane that surrounds the cartilage and the post-injury recovery is also inefficient due to lack of blood vessels and blood supply [1,13], though during the initial development stage of perichondrium, the regenerative potential of early mesenchymal progenitor cells aid to some extent [22,23]. Hence, without an adequate blood supply, the repair of cartilage defects can be slow and less effective [14,24–26]. Preparing an OC unit that is tailored to each individual's anatomy requires precise imaging, measurements, and surgical planning. The production of customized OC units becomes a more difficult and challenging task while considering all the functionalised requirements of a native OC unit [27–30].

Articular cartilage, despite its high water content (~80%), exhibits remarkable mechanical properties. The compressive modulus, a key indicator of cartilage stiffness, typically ranges from 0.53 to 1.82 MPa. Tensile strength, measuring the resistance to deformation before failure, is approximately 17 MPa. It is important to note that these values can vary depending on factors such as age, loading conditions, and disease progression state [31,32]. The special characteristic of articular cartilage is its dense ECM with a sparse distribution of highly specialized chondrocytes. Chondrocytes are adapted to low-oxygen (hypoxic) environments, and their metabolism and functions are optimized for these conditions [33]. When cartilage is injured or needs to be regenerated, creating an environment that mimics its natural hypoxic state is crucial for successful regeneration [33–35]. Depending upon the ECM composition type and arrangement of the chondrocytes, the articular cartilage is differentiated into different zones. They are the superficial tangential zone, the transition/middle zone, and the radial/deep zone. The orientation of collagen fibres and chondrocytes, proteoglycan, and water content in each zone is varied to act as an anatomic and functional bridge, providing the line of resistance to compressive forces [12,36,37]. These zonal variations in cartilage with varying cell densities and ECM compositions affect the healing potential and biomechanical properties of repaired tissue, making it difficult to reproduce the native tissue structure [25,37–39]. In addition to cartilage, the OC constitutes of subchondral bone made of the subchondral bone plate and the calcified cartilage zone which acts as the transition into articular cartilage often referred to as the ‘tide mark’ with the lead cellular population of hypertrophic chondrocytes [12]. During joint development, the subchondral bone is formed *via* endochondral ossification of the cartilage template at the secondary ossification centres of the bone epiphyses. This subchondral trabecular bone is highly vascularized and it provides nutrition to cartilage in addition to that from synovial fluid [40]. There for preparing a customised OC unit for regeneration pose specific hurdles when considering the anatomy of cartilage and bone due to the hypoxia sensitive nature of chondrocyte and the highly vascularised nature of bone.



**Figure 1.** Osteochondral (OC) unit. (a) Diagrammatic representation of OC unit (b) H&E staining of murine OC unit.

## 2.2. Engineering approaches to restoring the OC interface

An understanding of the structural and functional properties of OC units realizes that the lack of vascularisation and deficiency in nutrient circulation to specific compartments along with the stringent mechanical strength requirements and hierarchical tissue structure would pose the main challenge in restoring an OC unit with the aid of tissue-engineered construct. The existing standard procedures such as total knee transplantation with artificial material are successful in relieving pain and improving function, but the articular cartilage and subchondral bone are not fully restored and would deteriorate over time [41]. The high failure rates associated with total knee replacements (TKRs) underscore the necessity for innovative treatment strategies. Factors contributing to TKR failure include fractures induced by wear and fatigue, stress concentration, inclusions, and high carbon levels in biomaterials [42]. Racial disparities do not explain TKR failure, with risk factors such as non-osteoarthritis TKR indication and low surgeon volume playing a role [43]. Metal hypersensitivity is a known cause of unsatisfactory TKR outcome, especially in patients undergoing revision surgery, although a clear correlation with symptomatic knee after surgery is not fully established [44]. To address the limitations in current treatments, researchers focus on engineering to develop advanced tissue construct/OC substitutes for regeneration with matching mechanical stability that of native OC unit/cartilage and bone. However, many of the developed OC constructs satisfied all the functional and mechanical properties that of the native OC unit in the *in vitro* experimental conditions, but failed to recapitulate the same in the *in vivo* conditions. So it is the need of the hour to design OC constructs with at par performance in both *in vitro* and *in vivo* experimental set-ups at constant physiological, biological, and microenvironmental conditions. The various commercially available OC products for OC defect management are listed in Table 1.

**Table 1.** Commercially available products for OC defect management.

Commercially available OC TE product	Components	Key Features	Advantages	Disadvantages	Reference
<b>TruFit® (Smith &amp; Nephew)</b>	Poly DL-lactide-co-glycolide, Calcium sulfate, Polyglycolide fibers, Surfactant	Cylindrical implant	The material degrades in approximately 4–8 months	Not intended to provide structural support during the healing process	[45,46]
<b>Collagraft® (Nuecoll Inc.)</b>	Collagen, hydroxyapatite/tricalcium phosphate (HA/TCP) granules	Purified type I bovine collagen, commercially available as sterile strips (45 x 10 x 3 mm) rehydrated just prior to use, approved for use in the US and Japan	For the treatment of acute long bone fractures and traumatic osseous defects with bone marrow and rigid fixation	<i>In vivo</i> conditions only validate subchondral or bone support not validating cartilage regeneration	[47–50]
<b>ChondroMimetic™ (TiGenix NV)</b>	Collagen, GAG, Calcium phosphate.	The plug consists of a chondral layer with collagen and GAG and an osseous layer with collagen, GAG, and calcium phosphate	Shown to support the simultaneous natural repair mechanism of both articular cartilage and bone having defect range of $\leq 12$ mm diameter and $\leq 8$ mm depth	Only applicable to small chondral and subchondral lesions and clinical results are poor for larger lesions	[51]
<b>MaioRegen® (Med&amp;Care) (collagen-based 3D scaffold)</b>	Collagen, Magnesium enriched-HA	Using de-antigenated type I equine collagen	Good clinical outcome with complete graft integration in 78.3% of patients		[52]

Table 1. Cont.


Commercially available OC TE product	Components	Key Features	Advantages	Disadvantages	Reference
<b>BST-Cargel® (Piramal Life Sciences)</b>	Chitosan, Glycerophosphate, Autologous blood	Injectable hydrogel	This product has proved to be efficient in the initiation and amplification of the intrinsic wound healing processes of subchondral bone, as well as of the cartilage repair		[53–57]
<b>Gelrin C</b>	Polyethylene glycol diacrylate (PEG-DA), Fibrinogen	Biodegradable implant using denatured fibrinogen	Exposure to ultraviolet light converts the liquid into a soft, elastomeric hydrogel implant		[58,59]
<b>CaReS (Cartilage Regeneration System)</b>	Collagen, autologous cartilage cells	CaReS-OneStep is a cell-free matrix available	Support the cartilage regeneration	Only for cartilage regeneration and difficulty in getting autologous cartilage cells	[60]
<b>BioPoly RS Knee System (by BioPoly LLC)</b>	Ultra-high-molecular-weight polyethylene, hyaluronic acid	Femoral condyle resurfacing device	The device is designed to permit arthroscopic-assisted implantation to be quick and straightforward	Restricted to cartilage regeneration only	[61]

Table 1. Cont.

Commercially available OC TE product	Components	Key Features	Advantages	Disadvantages	Reference
<b>SaluCartilage™ (SaluMedica)</b>	Polyvinyl alcohol	Biocompatible and hydrophilic cylindrical device	This material mimics human cartilage in terms of water proportions and has been evaluated as a synthetic surface for the replacement of damaged cartilage	The hydrogel showed an inadequate connection to the bone and a risk of dislocation	[62]
<b>TruGraft™ (Osteobiologics)</b>	Poly(lactic-co-glycolic) acid (PLGA)		Support osteoblast proliferation and differentiation, high alkaline phosphatase activity, and deposition of a mineralized matrix used in OC repair		
<b>Agili-C™ (CartiHeal)</b>	Calcium carbonate, Aragonite, Hyaluronic acid	Calcium carbonate for the bone region, and aragonite and hyaluronic acid for the cartilage part	The implant shows a structure similar to natural bone with high pore interconnectivity essential for blood vessels, and the hyaluronic acid helps the ECM of the cartilage to be maintained with their proper characteristics		[63,64]
<b>HYAFF®11 (Fidia Advanced Biopolymers)</b>	It is composed of purified hyaluronan esterified in its glucuronic acid group with distinct types of alcohols	A biodegradable scaffold is used for the repair of chondral and OC lesions.	The advantage of having good cell adhesiveness even without coating and surface conditioning		[65,66]

### 2.3. OC constructs design considerations for implantation

One of the challenging factors in developing OC construct is the size and shape of the graft. The developed graft should be implantable in the defect site with self-molding ability *i.e.*, to be able to change the shape according to the size of the small as well as large OC lesions. The ideal material should be biocompatible, and non-toxic, along with sufficient mechanical strength to support the load bearing of both cartilage and bone in the OC unit [67]. Considering the size and shape of the implant for the OC unit, it is very significant that the integration between cartilage and bone along with articular surface contour should occur [68,69]. The articular surface of joints is typically curved and matched to the opposing joint surface. Restoring the native contour and curvature real time during repair is essential to prevent issues such as joint instability, abnormal loading, and decreased range of motion that could occur in long run [70–72]. Another important feature is that a load-bearing implant must satisfy all the essential parameters for providing support and strength to the host tissue. Thus, the repaired tissue must be able to withstand the mechanical forces without undergoing excessive wear or degradation [73,74]. In view of these factors, biomaterials like hydrogels and their composites with suitable mechanical stability gained more attention due to the ease of preparing zonal gradients for regenerating different layers of cartilage and aiding mineralisation for the underlying bone. Most of the commercially available OC constructs have cylindrical shapes, some others have rectangular shapes, and a limited number are available in liquid formulation (eg. hydrogels) that could be directly injected into the defect site. The types of commercially available OC constructs are summarized in Figure 2.



**Figure 2.** Commercially available OC constructs. (a) BST-CarGel (b) caReS cartilage-regeneration system (c) Gelrin C (d) Chondrocelect (e) BioPoly-rs-knee-system.

Mechanically robust, non-resorbable hydrogels have emerged as promising candidates for the permanent replacement of damaged cartilage tissue. These materials are designed to



mimic the structural and functional properties of native cartilage, offering a potential solution to the challenges associated with cartilage regeneration. Recent studies have focused on developing hydrogels with high moduli and hydration levels to replicate the unique mechanical behavior of cartilage. For instance, composite hydrogel systems incorporating a lubrication layer and a load-bearing layer have demonstrated exceptional compression modulus, creep recovery, and resistance to swelling [75,76]. Moreover, the incorporation of bioactive molecules, such as icariin, into poly(vinyl alcohol) (PVA)—based hydrogels has shown promise in promoting chondrocyte activity and cartilage repair [76]. To further enhance the performance of these hydrogels, research has explored the development of tunable architecture and mechanical properties. Dual crosslinked gelling systems, as described by Yu *et al.* (2022), have exhibited excellent osteogenic potential, suggesting their potential for bone cartilage interface applications [77]. Additionally, the incorporation of bioactive molecules like kartogenin into hydrogel composites has demonstrated the ability to create favourable microenvironments for cartilage regeneration, promoting cell growth, adhesion, and differentiation [78]. These advancements highlight the potential of mechanically robust, non-resorbable hydrogels as viable alternatives to biological grafting for the treatment of cartilage defects.

### 3. Biological approaches to restoring the OC interface

Recent studies on OC tissue restoration are mainly targeted to the complete regeneration of hyaline cartilage and the subchondral bone. Repairing the damaged articular cartilage back to its functionally normal state has been a major challenge for OC tissue engineering. Currently, the treatment methods such as bone marrow augmentation and stimulation mosaicplasty [79], microfracture [80], and autologous chondrocyte implantation [81] have been used for patients to relieve pain and associated difficulties. However, these are challenging scenarios including the limitations like availability of donor sites, the required size and shape of the OC autograft, and the dedifferentiation of chondrocytes during passaging in culture [23]. The succeeding section will precisely discuss the existing challenges in the currently used treatment approaches.

#### 3.1. Bone marrow stimulation and augmentation

Vascularization is essential to heal damaged mesenchymal tissue, [82] whereas in chondral defect, poor vascularization due to the lack of vascular, lymphatic, and nervous systems lead to a decreased rate of healing at the site of defect. The recent trends in cartilage regenerative research focuses on the stimulation of bone marrow progenitor cells that are only able to proliferate to the underlying bone plate [83]. Whereas, the management approach with multiple boreholes and fraying of the surface layer of the cortical bone is not feasible for arthritic patients. Only the complete removal of the sclerotic surface could promote healing of the lesion [79,84]. Stedman's Microfracture technique, in which repair of cartilage *via* bone marrow stimulation has the disadvantage of calcified cartilage layer formation [85]. The modified microfracture technology for defects smaller than 1cm which is called the nano

drilling method is becoming more popular today, showing initial clinical improvement post surgery but with an accelerated decline in clinical outcome scores and a higher failure rate during long-term follow-up [85–87].

### 3.2. OC autograft transfer

OC autograft transfer delivers viable, mature hyaline cartilage–bone units into chondral defects. The systematic review by Richeter *et al.*, (2016) found that ~90% of patients who underwent OC autograft transfer had good or excellent outcomes up to 10 years post surgery [26]. The autograft for this purpose was taken from areas of lower contact pressures on the weight-bearing articular surfaces of the knee [88,89]. It involves the harvesting of ‘plugs’ from regions of the distal femur that bear low loads (such as the intercondylar notch or medial or lateral trochlea) and promises a higher chance of successful donor graft incorporation and less risk of immune-mediated graft rejection. This method has more application in young and active patients with more load-bearing activities in the early postoperative period, *i.e.* nearly 6–8 months after surgery [90]. However, donor site morbidity and the availability of autologous grafts are the major limitations faced during OC autograft transplantation.

### 3.3. OC allograft transplantation

The bone marrow augmentation and stimulation techniques and OC autograft transfer have been reported to be unproductive or impracticable for lesions  $>2\text{ cm}^2$  [91,92]. Also, the repair of fibrocartilage using bone marrow augmentation and stimulation techniques yield physiological and biomechanical results mediocre to the normal native structure of articular cartilage. Perhaps in young and active patients, cell-based cartilage repair like autologous chondrocyte implantation remains a viable option for severe OC defects even though it necessitates two separate procedures and a prolonged recovery [90].

In an OC allograft transfer a fully thickened, viable articular cartilage is implanted, however, it is a single-stage technique that evades donor site morbidity, permitting the resurfacing of large defects, and produces a more natural, matching contour of the native recipient surface anatomy [93]. Recent studies based on OC allograft transfer reveal that there was improvement when comparing patient pre-surgical scores and patient-reported outcome scores, in knee chondral repair [94]. This technique is highly useful in overcoming extensive subchondral edema, unshouldered lesions, and restoration of bone loss [95].

### 3.4. Matrix induced -autologous chondrocyte implantation (MACI)

Autologous chondrocyte implantation (ACI) is a surgical technique for fully thickened cartilage lesions in knee joints. A small piece of normal cartilage at the site of the lesion is removed and cultured *in vitro* to enhance the number of cells and is re-implanted to the defect site. ChondroCelect® is the first commercially available cell-based product that successfully completed the entire development track from research to final product for knee cartilage

regeneration. This implant consists of chondrocytes derived from the patient's own cartilage surgically implanted, to induce the synthesis of hyaline cartilage at the tide mark of bone and cartilage to restore the native joint structure and functions [96]. In the last decade, a case series by Peterson *et al.*, 2010 disclosed that meniscal injuries occurring before ACI, or a history of bone marrow procedure before the MACI implantation do not affect the final results of ACI. However, the bipolar lesions at the site of defect and age of the host are the factors that interfere with the outcome [97]. Extended studies have revealed that some limitations which include delamination, dislodgment of the retained periosteal flap, hypertrophy of the periosteum, degeneration or failure of the cartilage repair, *etc.* occur after ACI procedure [98,99]. There are several modifications, which have been introduced to improve the quality of the ACI technique and they are considered as first, second, and third generation of ACI. When the first generation of ACI use suspended autologous cultured chondrocytes in combination with a periosteal patch, the second generation ACI techniques use other membranes (a collagen type I/III membrane) to retain autologous chondrocytes in the cartilage defect, whereas a cell-loaded membranes/ carriers/scaffolds are applied arthroscopically in the third generation MACI [100]. Even though the method of ACI improved the functional outcome, a small percentage of patients still needed revision surgeries [101]. Initially, MACI was limited to knee ACI and was gradually tried in other regions to treat localised full thickened cartilage defects [102].

The MACI technology is advanced and reduces the surgical complexity as it could be completed in minimum procedure time. Fibrin adhesive has also been used in MACI to facilitate chondrocyte migration from the membrane base to the healing tissue. Several positive outcome after the clinical application of the MACI implant in the animal and human knee have been reported [100,103–106]. The MACI technique replaced the need to suture the graft into the cartilage defect, and can be applied by arthroscopic technique, and decreases the stimulus for vasculogenic hypertrophy [107,108]. Cell-based repair of articular cartilage using autologous chondrocyte implantation has been demonstrated in the hip joint [109] recently.

Preclinical data characterizing cartilage healing are limited to short-term studies in rabbits, and sheep models and little information is available about the survival and efficacy of the MACI for cartilage repair. The equine model study by Nixon *et al.*, 2017 reveals that MACI appeared to improve cartilage healing in a critical-sized defect compared with collagen matrix alone [105]. The main limitation related to the use of ACI and MACI is that the implantation requires two surgical procedures for the patients, which could increase the morbidity of the treatment as well as the socioeconomic costs. If at all possible, a complete cartilage repair could be targeted in a solitary stage that accomplishes the goals of restoring hyaline-like repair tissue with durable and long-term functional quality.

#### **4. Challenges in the choice and design of scaffolds for OC regeneration**

Ideal biomaterials to be used as scaffolds for OC tissue regeneration should possess properties like biocompatibility, biodegradability, high porosity, compressibility, non-cytotoxicity, non-antigenicity, flexibility/elasticity, osteo-conductivity, and suitability

for chondrocyte cell attachment proliferation and differentiation [110]. The scaffolds should mimic the physico-chemical properties of native ECM in the OC tissue (both cartilage and subchondral bone), be able to provide mechanical support, and biochemical cues, and promote cell-matrix interaction for initiating the tissue regeneration process [111,112]. Due to the poor healing and limited regenerative capacity of the OC unit, chondral damage is considered irreversible, with limited functional restoration. According to the International Cartilage Repair Society (ICRS) criteria, partial thickness chondral damage is unable to heal itself as the subchondral bone presents a barrier between the defect and bone marrow. Whereas, in the case of full thickness condition the chondral defect is in direct contact with pluripotent mesenchymal stem cells. In the spontaneous healing process that occurs, the newly formed fibrocartilage fills the gap of the defect and acts as a part of hyaline cartilage. This newly developed fibrocartilage is poor in mechanical properties in comparison with native structure [113].

#### 4.1. Material for OC tissue engineering

It's worth noting that ongoing research aims to optimize the biomaterials and fabrication techniques, focusing to improve the functional integration between the cartilage and bone components and promote long-term tissue regeneration. Overcoming the limitations of biomaterials for OC tissue engineering is an active area of research. The type of biomaterial used to prepare scaffolds for OC tissue engineering are listed in Table 2.

**Table 2.** Type of biomaterials used/using currently for synthesis of OC unit.

Sl. No.	Biomaterials used/employed currently for the synthesis of OC unit	Advantage	Disadvantage	Reference
1	Natural Polymers (e.g., Collagen, Fibrin,)	Biocompatible, mimics the natural extracellular matrix (ECM), promotes cell attachment, and can facilitate tissue regeneration	Limited mechanical strength, potential for degradation over time, and lack of control over material properties	[114,115]
2	Synthetic Polymers (e.g., Poly(lactic acid) (PLA), Poly(glycolic acid) (PGA), Poly(caprolactone) (PCL), poly(D,L-lactide-co-glycolide) (PLG))	Tailorable mechanical properties, biodegradable, and can provide structural support during tissue regeneration	Lack of inherent bioactivity, potential for inflammation or immune response, and slower tissue integration compared to natural materials	[116,117]
3	Hydrogels (e.g., Hyaluronic acid, Alginate, Gelatin)	High water content, good biocompatibility, and ability to mimic the native cartilage ECM. Can provide a suitable environment for cell encapsulation and tissue growth	Limited mechanical properties, difficulty in achieving load-bearing capacity, and potential for swelling or degradation over time	[118–120]

Table 2. Cont.

Sl. No.	Biomaterials used/employed currently for the synthesis of OC unit	Advantage	Disadvantage	Reference
4	Resorbable Hydrogels	Biocompatible, injectable, the physical and chemical properties of the hydrogel tailored to specific clinical needs, support cell function and tissue formation	Limited initial mechanical strength, may require additional support structures	[121–123]
5	Ceramic-Based Scaffolds (e.g., Hydroxyapatite, Tricalcium phosphate)	Biocompatible, mimics the mineral phase of bone and can provide structural support. Facilitate bone ingrowth and integration	Brittle nature, limited ability to mimic cartilage properties, and potential for stress shielding	[124–126]
6	Composite Scaffolds	Combination of different biomaterials to mimic the OC interface. Allows for tailoring of mechanical and biological properties	Complex fabrication processes, the potential for material mismatch at the interface, and challenges in achieving seamless integration	[127–131]
7	Decellularized Extracellular Matrix (ECM)	Retains the natural ECM composition and architecture, supports cell adhesion and tissue regeneration, and provides bioactive cues	Limited availability, potential for immune response, and challenges in achieving consistent decellularization and sterilization	[132–136]
8	3D Printing/Bioprinting	Enables precise control over scaffold architecture, can incorporate multiple materials, and offers customization for patient-specific needs	Limited range of biomaterials suitable for printing, challenges in achieving proper mechanical properties, and long-term stability	[116,137,138]

#### 4.1.1. Decellularised cartilage

Recently, native ECM tissue-based materials with acellular component are in demand as they provide structural support, and enhance stem cell recruitment, and differentiation without any external inducible factors. Sutherland *et al.*, in their decellularised cartilage-based study provide evidence of osteogenesis and chondrogenesis *in vitro* [139]. The decellularised ECM (dECM) are fabricated in different methods, with whole tissue decellularisation, which can be easily fabricated without any technical trouble and could be lyophilised through decellularizing and recellularising of dense tissues. The powdered dECM in the freeze-dryer method could be used to mold scaffolds with adjustable geometry but have only poor

mechanical properties as compared to the whole tissue scaffolds. Recent studies on dECM-based materials in combination with hydrogels, polymeric solutions for 3D patterned printing, and electrospinning came up as hope in chondroinductive tissue regeneration in the OC unit [140,141].

#### 4.1.2. Gradient biphasic/triphasic scaffolds

A biomimetic gradient biphasic/triphasic scaffold must have a seamlessly integrated layer structure, suitable pore size, and excellent mechanical properties. Though tissue engineering fabrication and the implementation of bi-phasic scaffolds is a successful journey, the recapitulation of the depth-dependent features of native tissue remains a challenge. Additionally, the major limitations of engineered constructs are non-efficient nutrient transport and matrix accumulation which hinder regenerative tissue maturation within the central core of large constructs [142].

In the OC defect, the designed bi-phasic scaffold should initiate regeneration of both cartilage and subchondral bone segments. The scaffold appeared permissive to bone and cartilage tissue growth and penetration, ensuring the diffusion of nutrients and oxygen, as evident from neo-angiogenesis within a month [143]. The bi-phasic scaffold can be synthesised independently by different processes, further in which the individual layer could be combined [144]. According to Liu *et al.*, the novel bilayer OC graft consists of organic compound type I collagen incorporated chondral scaffold layer for the chondral regeneration and bioactive magnesium-doped hydroxyapatite (Mg/HA) crystals co-precipitated with the organic component for the subchondral layer [145]. The gradient triphasic scaffolds are particularly suited for the regeneration of cells according to their zonal discrimination. Many triphasic scaffolds are chondral scaffolds designed to reproduce the stratified structure and zonal characteristics of the cartilaginous region, while including the cell properties, phenotypes, alignment, zone-specific growth factors, matrix compositions, collagen fiber orientations, and mechanical properties [146]. In another study, Fu *et al.*, successfully fabricated a reproducible triphasic scaffold with inherent tissue functional properties and depth-dependent cellular organization by co-culture of mesenchymal cells and chondrocytes. This scaffold components included porous hollow fibers and cotton threads to augment nutrient transport. They concluded that the addition of cotton thread increases the matrix accumulation in the central core and change local modulus at the deep layer similar to that of native tissue, thus raising a real-world promise for the biomimetic repair of focal chondral defects [146].

Wang *et al.* demonstrated the use of a triphasic methylpropenylated gelatin hydrogel scaffold for OC defect repair, integrating chondroitin sulfate and hydroxyapatite to enhance chondrogenic and osteogenic capabilities [147]. Yu *et al.* reported the fabrication of an anisotropic hydrogel based on a decellularized extracellular matrix, employing the use of controlled diffusion to create gradient structures for cartilage injury repair. [148]. Gradient microgel suspensions can influence cell behavior and differentiation within porous scaffolds, and tuning of matrix formulation can steer divergent differentiation outcomes [149]. Weigel *et al.* presented a method to fabricate freestanding multimaterial sheets using


aspiration-based alignment of microgels, enabling spatially controlled functionality in polymer materials [150]. Camacho *et al.* introduced a solvent-cast 3D printing strategy for peptide-functionalized polymers to achieve surface functionalization in a single step, enabling spatially controlled biochemical cues for enhanced tissue regeneration [151]. The fabrication of reinforced biphasic scaffolds made from polyvinyl alcohol (PVA), gelatin, and polycaprolactone (PCL) optimised the scaffold's mechanical strength, thermal stability, and bio-functionality, indicating suitability for maxillofacial surgery applications [152].

#### 4.1.3. Biomimetic multiphasic scaffolds

There exist stringent requirements for biomimetic scaffolds in terms of OC tissue regeneration as they must recreate the features of a functional OC unit *i.e.*, biochemical, biomechanical, and biological features of the cartilage and subchondral bone [143]. The biomimetic scaffolds might mimic and simulate the composition of the natural extracellular matrix to repair OC defects [145].

Innovative 3-D printing developed *via* additive manufacturing technique or layer-by-layer manufacturing technique has come into existence to overcome the limitations of conventional scaffold manufacturing. This type of layer-by-layer manufacturing technique uses customized designing methods for the construction of 3-D layered scaffolds. Through such customized scaffold designing, it is possible to produce constructs that have suitable pore size, and mechanical properties and are capable of providing favourable microenvironment for the growth of cells specific to each layer within the interface. There are different types of additive manufacturing techniques to develop scaffolds with desired anatomical shapes [19,67]. The leading limitations of 3D bio-printing are that its structural integrity and mechanical properties will be different in the *in vivo* applications and the designing of scaffold for load-bearing tissues will be very difficult. Hence, hybrid 3-D printing technology evolved to overcome these limitations.

The zonal differentiation of the ECM component in the OC unit requires the synthesis of biomimetic ECM with varying mechanical strength, with ability to support the chondrocyte in each zone according to its function. According to this zonal differentiation, a 3-D bio-print for OC tissue must provide the same or similar properties as that of the native ECM. Hybrid 3-D bio-printing with multiple layers of different combinations of biomaterials can provide matching mechanical properties, pore size, and interconnectivity for the distribution and proliferation of chondrocytes within the construct/scaffold [153]. A diagrammatic representation of a 3-D bio-print for OC construct development is shown in Figure 3.



**Figure 3.** Diagrammatic representation of 3-D bio-print for OC construct development.

Current research in tissue engineering has focused on biomimetic multiphasic scaffolds with spatially controlled material properties to enhance tissue regeneration outcomes. Studies have highlighted the use of innovative scaffold designs, such as triply periodic minimal surfaces (TPMSs) [154], and the development of multifunctional core-shell particles for sequential ion release in bone engineering scaffolds [155]. Biomimetic hydrogels have also emerged as promising materials, offering tunable mechanical and biological properties for tissue repair and regeneration applications [156]. By mimicking the native tissue microenvironment and integrating bioactive substances, these scaffolds aim to improve cell adhesion, tissue integration, and overall therapeutic efficacy. The incorporation of spatially controlled material properties in these scaffolds represent a significant advancement in the field of tissue engineering, paving the way for more effective and tailored approaches to tissue regeneration [157].

## 5. Cell sources

### 5.1. Stem cells in OC tissue engineering

Due to the poor healing and limited regenerative capacity, chondral damage in the OC unit is considered irreversible with partial regeneration. Mesenchymal stem cells (MSC) are one of the best cell choices able to differentiate into multiple lineages such as chondral, bone, muscular, and tendon tissue. The widely used MSCs are adipose-derived MSC (ADMSC) and bone marrow-derived MSC (BDMSC) which are isolated from adipose tissue and bone marrow respectively and able to differentiate into osteoblasts, adipocytes, and chondrocytes [82].

Investigation by Kim *et al.*, on seeding human ADMSC on a transforming growth factor (TGF)- $\beta$ 3 encapsulated polylactide-co-caprolactone (PLCL) scaffold (supercritical carbon dioxide (CO<sub>2</sub>)-1,1,1,3,3,3-hexafluoro-2-propanol (HFIP) co-solvent system) revealed that scaffolds by a co-solvent system exhibited distinct improvement in the compressive E-modulus and deposition of extracellular matrix [158]. Another study by Zhang *et al.*, introduced an approach to promote cartilage formation by ADMSCs seeded polylactic-co-glycolic acid



(PLGA) scaffold exposed to dynamic compression in combination with exogenous SOX-9 treatment [159]. ADMSC chondrocyte co-culture-based study by Wang *et al.*, has revealed that in the presence of ECM components, robust articular cartilage matrix deposition and increased compressive moduli were attained [160]. A bilayered nanopatterned construct seeded with predifferentiated ADMSCs yielded a stratified bilayered hydrogel construct with improved repair quality of cartilage defects [161].

Then approaching to the bone marrow-derived stem cell studies, both bone marrow concentrate (BMC) and BDMSCs were used as cell sources. In the case of BMC, a concentrate graft derived from bone marrow consisting of a heterogeneous population of cells including MSCs [162] was used. BDMSC and BMC are widely used in one-step arthroscopic techniques, with BMC as the preferred source of choice. The main advantage of using BMC directly over BDMSC is that it could be directly used for implantation technique without the need for an extensive laboratory preparatory phase [163]. Hernigou *et al.*, in their BDMSCs-based comparative study in osteoarthritic patients revealed that the method of implantation of BDMSCs in subchondral bone is more effective than the intra-articular injection of the same dose of BDMSCs in postponing total knee arthroscopy [164]. All these MSC-based OC tissue regeneration studies require a standardised and validated method of obtaining large quantities of zone-specific chondrocytes derived from MSCs/BDMSCs-based tissue engineering approaches.

## 6. Recreating the microenvironment and translational challenges

As mentioned earlier, OC defects are considered the leading cause of disability worldwide, as spontaneous regeneration in this region is restricted due to the inaccessibility to progenitor cells and limited blood supply [165]. OC tissue engineering aims to regenerate functional tissue, mimicking the anatomical and physiological properties of injured cartilage and its subchondral bone. An OC tissue coculture system bilayered scaffold seeded with coculture of ATDC5 (chondrogenic cell line) and MC3T3-E1 (osteoblast cell line) cells in a dual-chamber perfusion bioreactor was described. The authors have studied the system through both *in vitro* co-culture of cartilage and bone cells, and *in silico* computational modelling of the microenvironment inside a micro-CT scanned during perfusion system. This system was shown to have desired microenvironment for OC tissue engineering and it can potentially be used as an inexpensive tool for testing newly developing pharmaceutical products for OC defects [165]. The two important tools that are used here for recreating the OC microenvironment for tissue engineering purpose, specifically enhanced the natural healing process are the bilayered scaffold and the bioreactor. Apart from the bi-phasic and multi-layered scaffolds, what is the contribution of a bioreactor for OC tissue remodelling purpose? This question raises new thoughts for the development and designing of bioreactors which are capable of providing a differential microenvironment for the growth and development of both cartilage and bone tissue segment separately.

Transport of nutrients and gas as well as the removal of waste is one of the other important consideration when designing a good bioreactor. One limiting condition is the amount of gas (oxygen) supplied and the amount reaching to cell. Gruenloh *et al.*, in their *in vitro* experiment demonstrated that the senescence of human embryonic stem cells is reduced

in the low oxygen (3%) or hypoxic condition, as well as the mobility of cells, were much higher at 5% CO<sub>2</sub> and ambient O<sub>2</sub> (normoxic condition) [166]. Yasui *et al.*, also observed that low oxygen conditions promote chondrogenesis in human synovial-derived mesenchymal stem cells in their *in vitro* experiments [167]. Thus, the cells of cartilage need a lower concentration of oxygen for their entire regeneration processes and that of the bone need a high concentration of oxygen for the same. While taking account of these matters, a controlled supply of oxygen is necessary for the regeneration of OC units in a bioreactor [168]. In the superficial zone, cartilage needs 7% of oxygen whereas in the deep zone it needs only 1%, a prevailing hypoxic condition is crucial along with other necessary factors for the regeneration [169]. Cartilage being avascular in nature, a good integration of OC unit with host system is a difficult task and would only be possible by providing a good microenvironment to keep the quality of regenerated OC unit similar to that of the native state.

Loss of regenerative cells through cell death after transplantation is the other challenging problem. As per Zhang *et al.*, and Robey *et al.*, almost half the population of transplanted cells die *via* inflammation, and apoptosis within 5 days after implantation, mainly due to the harsh host environmental conditions, [170,171]. Cellular senescence of transplanted cells such as mesenchymal stem cells and autologous chondrocytes occur due to the deprivation of anchorage-dependent cellular adhesion to the ECM. To conquer this cellular senescence after transplantation, it is better to incorporate certain moieties like RGD into the scaffold to enhance the interaction of cell adhesion molecules aiding in cell adhesion [172,173]. Whereas the senescence induced by the inflammatory response could be vanquished by using a scaffold that has anti-inflammatory properties [174]. Incorporating the anti-inflammatory and antioxidant molecules might enhance cellular proliferation and reduce apoptosis, cellular senescence, and inflammatory response after integration [175].

Recollecting on different arenas of OC tissue regeneration and repair, the crucial area on the clinical side is the translation challenge during OC graft transfer. Other than the challenges mentioned in the previous sections, the main clinical problem faced during transplantation surgery is the probability of acquiring cartilage damage from donor to recipient during integration. This damaged donor cartilage makes the recipient OC unit restore poorly, ultimately leading to transplantation failure. Another aspect to consider is the mismatching of the topology of the recipient joint with the graft making it unfit and leading to infection. The pain and associated bleeding after transplantation surgery is a challenging clinical complication because of donor site morbidity [176]. According to the view of surgeons, transplantation surgeries are difficult and require a congruence of multiple factors along with post-critical care for a successful outcome.

Host demographics like age, gender, and physical condition also play a major role in determining the response and integration of the implanted OC unit into host tissue. The rate of recovery after surgery for patients differ and could result in pain, discomfort, and swelling. Frank *et al.*, in their comparative study, reveal that the two sets of study population below the age of 40 and above the age of 40 have equally recovered after transplantation surgery. However, the rate of recovery in the aspects of recovery from pain, the extent of daily activities, and physical activities are more in the population below the age of 40 compared to the other group [177]. Recent clinical trials in the OC units regeneration are listed in Table 3.

**Table 3.** Recent clinical trials in the OC regeneration (details adapted from clinical trial.gov)

Sl.No.	Condition or disease	Clinical trials ongoing	Biomaterial used	Site and type of procedure	Study type	Primary outcome measure	Related References
1	Patient Satisfaction Graft Failure Osteo Arthritis Knee	Autologous Semitendinosus Tendon Graft as Meniscal Transplant - a Clinical Pilot Study	semitendinosus tendon	meniscal transplant in osteoarthritis -Surgical technique	Observational	Failure [ Time Frame: 2 years ] Surgical failure of transplant is defined as meniscus symptoms (joint line tenderness, swelling, locking, or positive McMurray) resulting in a need for re-arthroscopy and subtotal or total resection of the transplant.	[178–180]
2	Acute Knee Cartilage Injury/ Tear of Articular Cartilage of Knee	Evaluation of an Acellular OC Graft for Cartilage Lesions ("EAGLE") European Post Market Study	BioMatrix CRD™ biphasic scaffold contains type I collagen cartilage phase and $\beta$ -tricalcium-phosphate (80 %) with polylactic acid (PLA) (20 %) for subchondral bone	All patients will receive BioMatrix CRD to repair an articular cartilage lesion or OC defect	Observational 1	Rate of implant failure resulting in device removal and/or further surgical intervention due to a device-related complication	
3	Degenerative Lesion of Articular Cartilage of Knee	Randomized Controlled Trial of Microfracture Versus Adipose-Derived Stem Cells for the Treatment of Isolated Articular Cartilage Defects	adipose-derived stem cells and collagen scaffold	Cartilage degradation /adipose-derived stem cells Application and Microfracture	Interventional	Health Scores on the KOOS Questionnaire [ Time Frame: Completed at baseline, 6 months, 12 months, and 24 months post-operatively. ] The Knee Osteoarthritis Outcome Score (KOOS), a standard outcome questionnaire for the assessment of health-related quality of life, will be completed.	[181–189]
4	Cartilage Damage Cartilage Disease	All Autologous Cartilage Regeneration in the Treatment of the Knee Cartilage Defects: Pilot Study	healthy cartilage and the autologous platelet concentrate	Cartilage damage/ A one-step technique in which the healthy cartilage harvested is fragmented directly <i>in situ</i> and then mixed with the autologous platelet concentrate and directly injected into the cartilage defect.	Interventional	Change in knee functionality assessed by KOOS [ Time Frame: (before treatment, 6, 12, and 24 months postoperative )	[81,190–192]
5	Cartilage Damage	Randomized Controlled Trial Comparing Clinical, Outcomes of Instant MSC Product Accompanying Autologous Chondron Transplantation (IMPACT) for Focal Articular Cartilage Lesions of the Knee to Conservative Treatment	Autologous recycled chondrons (chondrocytes surrounded by pericellular matrix) with MSCs and mixed in Tisseel@(fibrinogen and thrombin concentrate)	Cartilage damage-Grade III or IV cartilage lesions of the knee ranging in size 2-8 cm <sup>2</sup> /the autologous defect-derived chondrons will be combined with allogeneic cryopreserved and thawed MSCs to enhance cartilage formation	Phase 3- Interventional	Clinical change on a scale of 0-100 [ Time Frame: At baseline, 3, 6 and 9 months ] KOOS-questionnaire (Knee injury and Osteoarthritis Outcome Score, 100 indicating no symptoms and 0 indicating extreme symptoms)	[193–195]

Table 3. Cont.

Sl.No.	Condition or disease	Clinical trials ongoing	Biomaterial used	Site and type of procedure	Study type	Primary outcome measure	Related References
6	Articular Cartilage Lesion of the Femoral Condyle	Prospective, Randomised, Open Label, Multicentre Phase-III Clinical Trial to Compare the Efficacy and Safety of the Treatment With the Autologous Chondrocyte Transplantation Product co.don chondrosphere (ACT3D-CS) With Microfracture in Subjects With Cartilage Defects of the Knee With a Defect Size Between 1 and 4 cm <sup>2</sup>	co.don chondrosphere®, a three-dimensional autologous chondrocyte transplantation product (ACT3D-CS)	Microfracture-Articular Cartilage Lesion of the Femoral Condyle/the Autologous Chondrocyte Transplantation Product co.Don Chondrosphere (ACT3D-CS) With Microfracture in Subjects With Cartilage Defects of the Knee With a Defect Size Between 1 and 4 cm <sup>2</sup>	Phase 3- Interventional	Change of overall KOOS (Knee Injury and Osteoarthritis Outcome Score)from baseline (Day 0)to final assessment compared between ACT3D-CS (co. don chondrosphere) and MF (microfracture)	
7	Articular Cartilage Lesion of the Femoral Condyle	A Comparative Clinical Trial for the Repair of Chondral Knee Defects: Transplantation of Autologous Cultured Chondrocytes vs. Autologous Mesenchymal Stem Cells Derived From Adipose Tissue	adipose tissue-derived stem cells and cultured autologous chondrocytes	Articular Cartilage Lesion of the Femoral Condyle-implantation	Phase 2- Interventional	Hyaline cartilage production for chondral knee lesions repair [ Time Frame: 18 months ]	[81,196,197]
8	Foreign-Body Reaction Inflammation Effusion (L) Knee Knee Pain Swelling	Instant MSC Product Accompanying Autologous Chondron Transplantation (IMPACT): Safety and Feasibility of a Single-stage Procedure for Focal Cartilage Lesions of the Knee	chondrons (chondrocytes with their pericellular matrix) and MSCs with fibrin carrier	focal articular cartilage lesions of the knee/one-step surgical procedure	Phase 2 Interventional	Safety: Adverse Events [ Time Frame: 18 months ] Adverse events rate	[198–200]
9	Osteochondritis Dissecans	Repair of Articular OC Defect	autologous chondrocyte-laden and biphasic cylindrical plug (DL-poly-lactide-co-glycolide, with its lower body impregnated with - tricalcium phosphate as the osseous phase)	symptomatic isolated osteochondritis at the femoral condyle was treated by replacing the pathological tissue with a biphasic cylindrical plug <i>via</i> the surgical method	Interventional	Knee Injury and Osteoarthritis Outcome Score [ Time Frame: 1 Year ]	

## 7. OC reconstruction for osteoarthritic conditions

Cartilage plays a crucial role in maintaining the homeostasis of synovial joints *via* uninterrupted synthesis and degradation of the cartilage niche. During the synthetic phase, chondrocytes continuously produce ECM. In the second phase, the enzyme produced by the chondrocytes (matrix metalloproteinase- MMPs) digests the matrix so that the synthetic step of ECM is inhibited, leading to cartilage erosion [201]. The MMPs, cytokines, and chemical mediators such as nitric oxide (NO), prostaglandins, interleukin-1b (IL-1b), tumor necrosis factor- $\alpha$  (TNF $\alpha$ ), IL-6, and IL-8 are elevated in the inflamed synovium due to the action of hypertrophic chondrocyte in the pathogenesis of OA [202]. The loss of joint flexibility due to limited movement and load bearing is the leading cause of structural and functional impairment of articular cartilage.

The pathophysiology of OA is that it affects the joint tissue even though the real cause is yet unknown. It may be due to biochemical, enzymatic, genetic, and biomechanical origin or their combination leading to changes, including the loss of typical structure and function of cartilage and subchondral bone. The narrowing of joints is a characteristic change during the disease progression. Repetitive impulsive loading increases bone formation associated with relative bone stiffening during the initial stages, followed by articular cartilage degeneration [203]. Recent studies in OA animal models and clinical samples have revealed that there exist location-specific and stage-specific pathological changes in OA development [204]. The requisites for an ideal OC biomimetic unit are made complex by the observation that there exist top-down and bottom-up calcification processes and the mineral pattern formed and deposited varies from hyper-mineralised stiffer carbonated hydroxyapatite in early stages to hypo-mineralised softer HAP. Further to this, is the expected scaffold functionality in the persisting inflammatory and degenerative hypoxic microenvironment demands the need for drug delivery scaffolds releasing anti-inflammatory molecules/radicals and stimulatory growth factors for cartilage regeneration. Hence, newer intelligent and smart biomaterial scaffolds are the need of the hour, which could detect and respond according to the changing microenvironment within the host body and could balance the mineral laydown along with endogenic cartilage progenitor homing capacity. Also, the patient-specific pathological milieu such as in OA and RA (Rheumatoid Arthritis) should be taken into account for the design of a precise and personalised OC scaffold.

## 8. Conclusion

Articular cartilage is a complex tissue characterized by limited regenerative capacity, reliant on diffusion for nutrient exchange, and possessing unique mechanical properties. The subchondral bone plays a crucial role in cartilage metabolism, yet its presence complicates tissue regeneration efforts in Osteoarthritis. Reproducing the intricate structure and function of the native OC unit remains a significant challenge. Current treatment options, including total knee replacement, often fall short of providing long-term sustained solutions. To address this unmet clinical need, there is a growing focus on developing innovative biomaterials and

scaffolds capable of mimicking the native OC unit. While various materials have been investigated, the achievement of optimal clinical outcomes requires careful consideration of factors such as size, shape, mechanical properties, biocompatibility, and the ability to support zonal regeneration. Hydrogels, in particular, show promise as regenerative biomaterials for designing resorbable matrices due to their tunable properties and potential to create biomimetic structures. Cell-based therapies, especially those utilizing MSCs, offer additional opportunities for OC regeneration. However, challenges related to cell sourcing, scaffold-cell interactions, and optimum bioreactor conditions need to be addressed. Moreover, translating promising preclinical findings into successful clinical applications requires careful consideration of factors such as cell survival, scaffold integration, and long-term tissue function. Future research should focus on developing biomaterials with enhanced bioactivity and mechanical properties, optimised cell delivery and differentiation strategies and standardized bioreactors environment in creating functional OC constructs. Ultimately, a comprehensive understanding of the complex interplay between cartilage, bone, and the surrounding microenvironment is essential for developing effective therapies to restore and maintain joint function. Effective OC unit regeneration holds immense potential to improve joint function outcomes specifically in pathological scenarios of Osteoarthritis patients.

### **Acknowledgments**

The first author gratefully acknowledges the facilities provided by the University of Kerala and Jawaharlal Nehru Tropical Botanical Garden and Research Institute, Department of Science and Technology (DST), Govt. of India, for research fellowship under the DST-INSPIRE Fellowship scheme (IF180191). The corresponding author acknowledges the UGC-BSR Faculty Fellowship program (F.No.4-5(11)2019(BSR), for providing financial support.

### **Conflicts of interests**

The authors declare that there are no conflicts of interest.

### **Authors' contribution**

Jalaja Aswathy contributed to the investigation, data curation, and writing of the original draft. Josna Joseph was involved in the investigation, data curation, and writing, specifically in the review and editing stages. Annie Abraham provided support in the resources, conceptualization, validation, and formal analysis, and also contributed to the writing through review and editing, as well as to visualization and supervision.

### **References**

- [1] Roseti L, Desando G, Cavallo C, Petretta M, Grigolo B. Articular Cartilage Regeneration in Osteoarthritis. *Cells*. 2019, 8(11):1305.

- [2] Cimmino MA, Parisi M, Moggiana GL, Maio T, Mela GS. Prevalence of self-reported peripheral joint pain and swelling in an Italian population: the Chiavari study. *Clin. Exp. Rheumatol.* 2001, 19(1):35–40.
- [3] Pearle AD, Warren RF, Rodeo SA. Basic Science of Articular Cartilage and Osteoarthritis. *Clin. Sports Med.* 2005, 24(1):1–12.
- [4] Osteoarthritis. Available: <https://www.who.int/news-room/fact-sheets/detail/osteoarthritis> (accessed on 17 Aug 2023).
- [5] Long H, Liu Q, Yin H, Wang K, Diao N, *et al.* Prevalence Trends of Site-Specific Osteoarthritis From 1990 to 2019: Findings From the Global Burden of Disease Study 2019. *Arthritis Rheumatol.* 2022, 74(7):1172–1183.
- [6] Sancheti P, Shetty VD, Dhillon MS, Sprague SA, Bhandari M. India-Based Knee Osteoarthritis Evaluation (iKare): A Multi-Centre Cross-Sectional Study on the Management of Knee Pain and Early Osteoarthritis in India. *Clin Orthop Surg.* 2017, 9(3):286–294.
- [7] Chopra A, Patil J, Billempelly V, Relwani J, Tandle HS. Prevalence of rheumatic diseases in a rural population in western India: a WHO-ILAR COPCORD Study. *J Assoc Physicians India.* 2001, 49:240–246.
- [8] Pal CP, Singh P, Chaturvedi S, Pruthi KK, Vij A. Epidemiology of knee osteoarthritis in India and related factors. *Indian J. Orthop.* 2016, 50(5):518–522.
- [9] Singh J. Effects of exercise rehabilitation programme on osteoarthritic knee with special reference to biochemical changes. 2010. Available: <http://shodhganga.inflibnet.ac.in:8080/jspui/handle/10603/2893> (accessed on 31 May 2022).
- [10] Vyas C, Poologasundarampillai G, Hoyland J, Bartolo P. *Biomedical Composites*, 2nd ed. St Louis: Elsevier, 3D printing of biocomposites for osteochondral tissue engineering. 2017, pp. 261–302.
- [11] Di Luca A, Van Blitterswijk C, Moroni L. The osteochondral interface as a gradient tissue: from development to the fabrication of gradient scaffolds for regenerative medicine. *Birth Defects Res. C Embryo Today Rev.* 2015, 105(1):34–52.
- [12] Sophia Fox AJ, Bedi A, Rodeo SA. The basic science of articular cartilage: structure, composition, and function. *Sports Health.* 2009, 1(6):461–468.
- [13] Chang LR, Marston G, Martin A. Anatomy, Cartilage. 2022. Available: <http://www.ncbi.nlm.nih.gov/books/NBK532964/> (accessed on 18 Jul 2022).
- [14] Wang Z, Liu B, Lin K, Duan C, Wang C. The presence and degradation of nerve fibers in articular cartilage of neonatal rats. *J. Orthop. Surg. Res.* 2022, 17(1):331.

- [15] OHara BP, Urban JP, Maroudas A. Influence of cyclic loading on the nutrition of articular cartilage. *Ann. Rheum. Dis.* 1990, (7):536–539.
- [16] Su Z, Zong Z, Deng J, Huang J, Liu G, *et al.* Lipid Metabolism in Cartilage Development, Degeneration, and Regeneration. *Nutrients.* 2022, 14(19):3984.
- [17] Wang Y, Wei L, Zeng L, He D, Wei X. Nutrition and degeneration of articular cartilage. *Knee Surg. Sports Traumatol. Arthrosc.* 2013, 21(8):1751–1762.
- [18] Flowers SA, Zieba A, Örnros J, Jin C, Rolfson O, *et al.* Lubricin binds cartilage proteins, cartilage oligomeric matrix protein, fibronectin and collagen II at the cartilage surface. *Sci. Rep.* 2017, 7:13149.
- [19] Morouço P, Fernandes C, Lattanzi W. Challenges and Innovations in Osteochondral Regeneration: Insights from Biology and Inputs from Bioengineering toward the Optimization of Tissue Engineering Strategies. *J. Funct. Biomater.* 2021, 12(1):17.
- [20] Watkins AR, Reesink HL. Lubricin in experimental and naturally occurring osteoarthritis: a systematic review. *Osteoarthr. Cartil.* 2020, 28(10):1303–1315.
- [21] Jay GD, Waller KA. The biology of lubricin: near frictionless joint motion. *Matrix Biol.* 2014, 39:17–24.
- [22] Ono N, Ono W, Nagasawa T, Kronenberg HM. A subset of chondrogenic cells provides early mesenchymal progenitors in growing bones. *Nat. Cell Biol.* 2014, 16(12):1157–67.
- [23] Murata D, Fujimoto R, Nakayama K. Osteochondral Regeneration Using Adipose Tissue-Derived Mesenchymal Stem Cells. *Int. J. Mol. Sci.* 2020, 21(10):3589.
- [24] Articular Cartilage Restoration, 2023. Available: <https://www.orthoinfo.org/en/treatment/articular-cartilage-restoration/> (accessed on 17 Aug 2023).
- [25] Silver FH, Glasgold AI. Cartilage wound healing. An overview. *Otolaryngol. Clin. North Am.* 1995, 28(5):847–864.
- [26] Richter DL, Schenck RC, Wascher DC, Treme G. Knee Articular Cartilage Repair and Restoration Techniques. *Sports Health Multidiscip. Approach.* 2016, 8(2):153–160.
- [27] Segaran N, Saini G, Mayer JL, Naidu S, Patel I, *et al.* Application of 3D Printing in Preoperative Planning. *J. Clin. Med.* 2021, 10(5):917.
- [28] Meyer-Szary J, Luis MS, Mikulski S, Patel A, Schulz F, *et al.* The Role of 3D Printing in Planning Complex Medical Procedures and Training of Medical Professionals—Cross-Sectional Multispecialty Review. *Int J Environ Res Public Health.* 2022 Mar 11;19(6):3331.
- [29] Bastawrous S, Wu L, Liacouras PC, Levin DB, Ahmed MT, Strzelecki B, *et al.* Establishing 3D Printing at the Point of Care: Basic Principles and Tools for Success. *RadioGraphics.* 2022 Mar;42(2):451–68.



- [30] Bozkurt Y, Karayel E. 3D printing technology; methods, biomedical applications, future opportunities and trends. *J Mater Res Technol*. 2021 Sep 1;14:1430–50.
- [31] Akizuki S, Mow VC, Müller F, Pita JC, Howell DS, Manicourt DH. Tensile properties of human knee joint cartilage: I. Influence of ionic conditions, weight bearing, and fibrillation on the tensile modulus. *J Orthop Res Off Publ Orthop Res Soc*. 1986;4(4):379–92.
- [32] Little CJ, Bawolin NK, Chen X. Mechanical properties of natural cartilage and tissue-engineered constructs. *Tissue Eng Part B Rev*. 2011 Aug;17(4):213–27.
- [33] Schipani E, Ryan HE, Didrickson S, Kobayashi T, Knight M, Johnson RS. Hypoxia in cartilage: HIF-1 $\alpha$  is essential for chondrocyte growth arrest and survival. *Genes Dev*. 2001 Nov 1;15(21):2865–76.
- [34] Li H, Li X, Jing X, Li M, Ren Y, Chen J, *et al*. Hypoxia promotes maintenance of the chondrogenic phenotype in rat growth plate chondrocytes through the HIF-1 $\alpha$ /YAP signaling pathway. *Int J Mol Med*. 2018 Dec 1;42(6):3181–92.
- [35] Pfander D, Gelse K. Hypoxia and osteoarthritis: how chondrocytes survive hypoxic environments. *Curr Opin Rheumatol*. 2007 Sep;19(5):457–62.
- [36] Eschweiler J, Horn N, Rath B, Betsch M, Baroncini A, Tingart M, *et al*. The Biomechanics of Cartilage—An Overview. *Life*. 2021 Apr 1;11(4):302.
- [37] Dehghan-Baniani D, Mehrjou B, Chu PK, Lee WYW, Wu H. Recent Advances in “Functional Engineering of Articular Cartilage Zones by Polymeric Biomaterials Mediated with Physical, Mechanical, and Biological/Chemical Cues.” *Adv Healthc Mater*. 2023;12(10):2202581.
- [38] Zhu D, Tong X, Trinh P, Yang F. Mimicking Cartilage Tissue Zonal Organization by Engineering Tissue-Scale Gradient Hydrogels as 3D Cell Niche. *Tissue Eng Part A*. 2018 Jan 1;24(1–2):1–10.
- [39] Medvedeva EV, Grebenik EA, Gornostaeva SN, Telpuhov VI, Lychagin AV, Timashev PS, *et al*. Repair of Damaged Articular Cartilage: Current Approaches and Future Directions. *Int J Mol Sci*. 2018 Aug 11;19(8):2366.
- [40] Imhof H, Sulzbacher I, Grampp S, Czerny C, Youssefzadeh S, Kainberger F. Subchondral bone and cartilage disease: a rediscovered functional unit. *Invest Radiol*. 2000 Oct;35(10):581–8.
41. Elisseeff J, Puleo C, Yang F, Sharma B. Advances in skeletal tissue engineering with hydrogels. *Orthod Craniofac Res*. 2005 Aug;8(3):150–61.
42. Pieretti EF, Leivas TP, Pillis MF, Neves MDM das. Failure Analysis of Metallic Orthopedic Implant for Total Knee Replacement. *Mater Sci Forum*. 2020;1012:471–6.

43. Bass AR, Mehta B, Szymonifka J, Finik J, Lyman S, Lai EY, *et al.* Racial Disparities in Total Knee Replacement Failure As Related to Poverty. *Arthritis Care Res.* 2019;71(11):1488–94.
44. Saccomanno MF, Sircana G, Masci G, Cazzato G, Florio M, Capasso L, *et al.* Allergy in total knee replacement surgery: Is it a real problem? *World J Orthop.* 2019 Feb 18;10(2):63–70.
45. Melton J, Wilson A, Chapman-Sheath P, Cossey A. TruFit CB® bone plug: Chondral repair, scaffold design, surgical technique and early experiences. *Expert Rev Med Devices.* 2010 May 1;7:333–41.
46. Verhaegen J, Clockaerts S, Van Osch GJVM, Somville J, Verdonk P, Mertens P. TruFit Plug for Repair of Osteochondral Defects—Where Is the Evidence? Systematic Review of Literature. *Cartilage.* 2015 Jan;6(1):12–9.
47. Alvis M, Lalor P, Brown M, Morgan R, Reddi A. 0680 - SUCCESSFUL INDUCTION OF NEW BONE FORMATION BY COLLAGRAFT.
48. Scrip [Internet]. 2001 [cited 2023 Jul 1]. NeuColl's Collagraft. Available from: <https://scrip.pharmaintelligence.informa.com/MT015615/NeuColls-Collagraft>
49. Pei M, He F, Boyce BM, Kish VL. Repair of full-thickness femoral condyle cartilage defects using allogeneic synovial cell-engineered tissue constructs. *Osteoarthritis Cartilage.* 2009 Jun;17(6):714–22.
50. Roberts SJ, Geris L, Kerckhofs G, Desmet E, Schrooten J, Luyten FP. The combined bone forming capacity of human periosteal derived cells and calcium phosphates. *Biomaterials.* 2011 Jul;32(19):4393–405.
51. Getgood A, Henson F, Skelton C, Brooks R, Guehring H, Fortier LA, *et al.* Osteochondral tissue engineering using a biphasic collagen/GAG scaffold containing rhFGF18 or BMP-7 in an ovine model. *J Exp Orthop.* 2014 Sep 26;1(1):13.
52. Christensen BB. Autologous tissue transplantations for osteochondral repair. *Dan Med J.* 2016 Apr;63(4):B5236.
53. Frappier J, Stanish W, Brittberg M, Steinwachs M, Crowe L, Castelo D, *et al.* Economic evaluation of BST-CarGel as an adjunct to microfracture vs microfracture alone in knee cartilage surgery. *J Med Econ.* 2014 Apr;17(4):266–78.
54. Hoemann CD, Tran-Khanh N, Chevrier A, Chen G, Lascau-Coman V, Mathieu C, *et al.* Chondroinduction Is the Main Cartilage Repair Response to Microfracture and Microfracture With BST-CarGel: Results as Shown by ICRS-II Histological Scoring and a Novel Zonal Collagen Type Scoring Method of Human Clinical Biopsy Specimens. *Am J Sports Med.* 2015 Oct;43(10):2469–80.

55. Rhee C, Amar E, Glazebrook M, Coday C, Wong IH. Safety Profile and Short-term Outcomes of BST-CarGel as an Adjunct to Microfracture for the Treatment of Chondral Lesions of the Hip. *Orthop J Sports Med.* 2018 Aug;6(8):2325967118789871.
56. Stanish WD, McCormack R, Forriol F, Mohtadi N, Pelet S, Desnoyers J, *et al.* Novel scaffold-based BST-CarGel treatment results in superior cartilage repair compared with microfracture in a randomized controlled trial. *J Bone Joint Surg Am.* 2013 Sep 18;95(18):1640–50.
57. Steinwachs M, Cavalcanti N, Mauuva Venkatesh Reddy S, Werner C, Tschopp D, Choudur HN. Arthroscopic and open treatment of cartilage lesions with BST-CARGEL scaffold and microfracture: A cohort study of consecutive patients. *The Knee.* 2019 Jan;26(1):174–84.
58. McNickle AG, Provencher MT, Cole BJ. Overview of existing cartilage repair technology. *Sports Med Arthrosc Rev.* 2008 Dec;16(4):196–201.
59. Schreiner MM, Raudner M, Szomolanyi P, Ohel K, Ben-Zur L, Juras V, *et al.* Chondral and Osteochondral Femoral Cartilage Lesions Treated with GelrinC: Significant Improvement of Radiological Outcome Over Time and Zonal Variation of the Repair Tissue Based on T2 Mapping at 24 Months. *Cartilage.* 2021 Dec;13(1 Suppl):604S-616S.
60. Andereya S, Maus U, Gavenis K, Müller-Rath R, Miltner O, Mumme T, *et al.* [First clinical experiences with a novel 3D-collagen gel (CaReS) for the treatment of focal cartilage defects in the knee]. *Z Orthop Ihre Grenzgeb.* 2006;144(3):272–80.
61. Nehrer S, Domayer S, Dorotka R, Schatz K, Bindreiter U, Kotz R. Three-year clinical outcome after chondrocyte transplantation using a hyaluronan matrix for cartilage repair. *Eur J Radiol.* 2006 Jan;57(1):3–8.
62. Lange J, Follak N, Nowotny T, Merk H. [Results of SaluCartilage implantation for stage IV chondral defects in the knee joint area]. *Unfallchirurg.* 2006 Mar;109(3):193–9.
63. Admin C. FDA approves CartiHeal’s Implant for the Treatment of Cartilage and Osteochondral Defects [Internet]. *The Future of joint Repair.* 2022 [cited 2023 Jul 1]. Available from: <https://www.cartiheal.com/news/bioventus-makes-15-million-equity-investment-in-cartiheal-with-an-agreed-option-structure-to-acquire-company-upon-milestone-achievements-https-ca-finance-yahoo-com-news-bioventus-makes-15-million-2-3/>

64. Agili-CTM Implant Performance Evaluation - Full Text View - ClinicalTrials.gov [Internet]. [cited 2023 Jul 1]. Available from: <https://clinicaltrials.gov/ct2/show/NCT03299959>
65. Hyaluronan Biodegradable Scaffold for Small-caliber Artery Grafting: Preliminary Results in an Animal Model. *Eur J Vasc Endovasc Surg.* 2006 Oct 1;32(4):411–7.
66. Valentini RF, Kim HD. Hyaluronan based biodegradable scaffolds for tissue repair [Internet]. WO1997045532A1, 1997 [cited 2023 Jan 24]. Available from: <https://patents.google.com/patent/WO1997045532A1/en>
67. Gadjanski I, Vunjak-Novakovic G. Challenges in engineering osteochondral tissue grafts with hierarchical structures Ivana Gadjanski, Gordana Vunjak Novakovic. *Expert Opin Biol Ther.* 2015 Nov;15(11):1583–99.
68. Jacob G, Shimomura K, Nakamura N. Osteochondral Injury, Management and Tissue Engineering Approaches. *Front Cell Dev Biol.* 2020 Nov 4;8:580868.
69. Fan X, Wu X, Crawford R, Xiao Y, Prasadam I. Macro, Micro, and Molecular. Changes of the Osteochondral Interface in Osteoarthritis Development. *Front Cell Dev Biol.* 2021 May 10;9:659654.
70. Williams GM, Chan EF, Temple-Wong MM, Bae WC, Masuda K, Bugbee WD, *et al.* Shape, Loading, and Motion in the Bioengineering Design, Fabrication, and Testing of Personalized Synovial Joints. *J Biomech.* 2010 Jan 5;43(1):156.
71. Brown TD, Elkins JM, Pedersen DR, Callaghan JJ. Impingement and Dislocation in Total HIP Arthroplasty: Mechanisms and Consequences. *Iowa Orthop J.* 2014;34:1–15.
72. Berthold DP, Muench LN, Dyrna F, Mazzocca AD, Garvin P, Voss A, *et al.* Current concepts in acromioclavicular joint (AC) instability – a proposed treatment algorithm for acute and chronic AC-joint surgery. *BMC Musculoskelet Disord.* 2022 Dec 9;23(1):1078.
73. Chen L, Zheng JJY, Li G, Yuan J, Ebert JR, Li H, *et al.* Pathogenesis and clinical management of obesity-related knee osteoarthritis: Impact of mechanical loading. *J Orthop Transl.* 2020 May 15;24:66–75.
74. Davis S, Roldo M, Blunn G, Tozzi G, Roncada T. Influence of the Mechanical Environment on the Regeneration of Osteochondral Defects. *Front Bioeng Biotechnol.* 2021 Jan 27;9:603408.
75. Demott CJ, Jones MR, Chesney CD, Grunlan MA. Adhesive Hydrogel Building Blocks to Reconstruct Complex Cartilage Tissues. *ACS Biomater Sci Eng.* 2023 Apr 10;9(4):1952–60.

76. Zhao W, Zhang Y, Zhao X, Sheng W, Ma S, Zhou F. Mechanically Robust Lubricating Hydrogels Beyond the Natural Cartilage as Compliant Artificial Joint Coating. *Adv Sci*. n/a(n/a):2401000.
77. Xiang C, Guo Z, Zhang Q, Wang Z, Li X, Chen W, *et al.* Physically crosslinked poly(vinyl alcohol)-based hydrogels for cartilage tissue engineering. *Mater Des*. 2024 Jul 1;243:113048.
78. Yu T, Zhang L, Dou X, Bai R, Wang H, Deng J, *et al.* Mechanically Robust Hydrogels Facilitating Bone Regeneration through Epigenetic Modulation. *Adv Sci*. 2022;9(32):2203734.
79. Johnson LL. Arthroscopic abrasion arthroplasty historical and pathologic perspective: Present status. *Arthrosc J Arthrosc Relat Surg*. 1986 Jan 1;2(1):54–69.
80. Steadman JR, Briggs KK, Rodrigo JJ, Kocher MS, Gill TJ, Rodkey WG. Outcomes of microfracture for traumatic chondral defects of the knee: average 11-year follow-up. *Arthroscopy*. 2003 May 1;19(5):477–84.
81. Brittberg M, Lindahl A, Nilsson A, Ohlsson C, Isaksson O, Peterson L. Treatment of deep cartilage defects in the knee with autologous chondrocyte transplantation. *N Engl J Med*. 1994 Oct 6;331(14):889–95.
82. Pill K, Hofmann S, Redl H, Holnthoner W. Vascularization mediated by mesenchymal stem cells from bone marrow and adipose tissue: a comparison. *Cell Regen*. 2015 Oct 23;4:8.
83. Brittberg M, Slynarski K, editors. *Lower Extremity Joint Preservation: Techniques for Treating the Hip, Knee, and Ankle* [Internet]. Cham: Springer International Publishing; 2021 [cited 2022 May 31]. Available from: <http://link.springer.com/10.1007/978-3-030-57382-9>
84. A method of resurfacing osteoarthritis knee joints – ScienceOpen [Internet]. [cited 2022 Jun 1]. Available from: <https://www.scienceopen.com/document?vid=404b08e4-b48c-4032-944c-c13fe5b7f085>
85. Steadman JR, Rodkey WG, Rodrigo JJ. Microfracture: surgical technique and rehabilitation to treat chondral defects. *Clin Orthop*. 2001 Oct;(391 Suppl):S362-369.
86. Mithoefer K, McAdams T, Williams RJ, Kreuz PC, Mandelbaum BR. Clinical Efficacy of the Microfracture Technique for Articular Cartilage Repair in the Knee: An Evidence-Based Systematic Analysis. *Am J Sports Med*. 2009 Oct 1;37(10):2053–63.
87. Erggelet C, Vavken P. Microfracture for the treatment of cartilage defects in the knee joint – A golden standard? *J Clin Orthop Trauma*. 2016;7(3):145–52.

88. Garretson RB, Katolik LI, Verma N, Beck PR, Bach BR, Cole BJ. Contact pressure at osteochondral donor sites in the patellofemoral joint. *Am J Sports Med.* 2004 Jun;32(4):967–74.
89. Jakob RP, Franz T, Gautier E, Mainil-Varlet P. Autologous osteochondral grafting in the knee: indication, results, and reflections. *Clin Orthop.* 2002 Aug;(401):170–84.
90. Haber DB, Logan CA, Murphy CP, Sanchez A, LaPrade RF, Provencher MT. OSTEOCHONDRAL ALLOGRAFT TRANSPLANTATION for the KNEE: POST-OPERATIVE REHABILITATION. *Int J Sports Phys Ther.* 2019 Jun;14(3):487–99.
91. Gudas R, Kalesinskas RJ, Kimtys V, Stankevicius E, Toliuisis V, Bernotavicius G, *et al.* A prospective randomized clinical study of mosaic osteochondral autologous transplantation *versus* microfracture for the treatment of osteochondral defects in the knee joint in young athletes. *Arthrosc J Arthrosc Relat Surg Off Publ Arthrosc Assoc N Am Int Arthrosc Assoc.* 2005 Sep;21(9):1066–75.
92. Knutsen G, Drogset JO, Engebretsen L, Grønvedt T, Isaksen V, Ludvigsen TC, *et al.* A randomized trial comparing autologous chondrocyte implantation with microfracture. Findings at five years. *J Bone Joint Surg Am.* 2007 Oct;89(10):2105–12.
93. LaPrade RF, Botker J, Herzog M, Agel J. Refrigerated osteoarticular allografts to treat articular cartilage defects of the femoral condyles. A prospective outcomes study. *J Bone Joint Surg Am.* 2009 Apr;91(4):805–11.
94. Levy YD, Görtz S, Pulido PA, McCauley JC, Bugbee WD. Do Fresh Osteochondral Allografts Successfully Treat Femoral Condyle Lesions? *Clin Orthop.* 2013 Jan;471(1):231–7.
95. Görtz S, Bugbee WD. Allografts in articular cartilage repair. *Instr Course Lect.* 2007;56:469–80.
96. Clar C, Cummins E, McIntyre L, Thomas S, Lamb J, Bain L, *et al.* Clinical and cost-effectiveness of autologous chondrocyte implantation for cartilage defects in knee joints: systematic review and economic evaluation [Internet]. NIHR Health Technology Assessment programme: Executive Summaries. NIHR Journals Library; 2005 [cited 2022 Jun 16]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK62302/>
97. Peterson L, Vasiliadis HS, Brittberg M, Lindahl A. Autologous chondrocyte implantation: a long-term follow-up. *Am J Sports Med.* 2010 Jun;38(6):1117–24.
98. Haleem A, Chu C. Advances in Tissue Engineering Techniques for Articular Cartilage Repair. *Oper Tech Orthop.* 2010 Jun;20(2):76–89.

99. Cogan CJ, Friedman J, You J, Zhang AL, Feeley BT, Ma CB, *et al.* Prior Bone Marrow Stimulation Surgery Influences Outcomes After Cell-Based Cartilage Restoration: A Systematic Review and Meta-analysis. *Orthop J Sports Med.* 2021 Sep 24;9(9):23259671211035384.
100. Brittberg M. Cell carriers as the next generation of cell therapy for cartilage repair: a review of the matrix-induced autologous chondrocyte implantation procedure. *Am J Sports Med.* 2010 Jun;38(6):1259–71.
101. Harris JD, Siston RA, Brophy RH, Lattermann C, Carey JL, Flanigan DC. Failures, re-operations, and complications after autologous chondrocyte implantation--a systematic review. *Osteoarthritis Cartilage.* 2011 Jul;19(7):779–91.
102. Steinmetz G, Hamilton J, Fernandes C, Bond J. Matrix-Induced Autologous Chondrocyte Implantation for a Glenoid Chondral Defect: A Case Report. *JBJS Case Connect.* 2020 Jun;10(2):e0264.
103. Ebert JR, Robertson WB, Woodhouse J, Fallon M, Zheng MH, Ackland T, *et al.* Clinical and Magnetic Resonance Imaging–Based Outcomes to 5 Years After Matrix-Induced Autologous Chondrocyte Implantation to Address Articular Cartilage Defects in the Knee. *Am J Sports Med.* 2011 Apr 1;39(4):753–63.
104. Enea D, Cecconi S, Busilacchi A, Manzotti S, Gesuita R, Gigante A. Matrix-induced autologous chondrocyte implantation (MACI) in the knee. *Knee Surg Sports Traumatol Arthrosc.* 2012 May 1;20(5):862–9.
105. Nixon AJ, Sparks HD, Begum L, McDonough S, Scimeca MS, Moran N, *et al.* Matrix-Induced Autologous Chondrocyte Implantation (MACI) Using a Cell-Seeded Collagen Membrane Improves Cartilage Healing in the Equine Model. *J Bone Joint Surg Am.* 2017 Dec 6;99(23):1987–98.
106. Vijayan S, Bartlett W, Bentley G, Carrington RWJ, Skinner JA, Pollock RC, *et al.* Autologous chondrocyte implantation for osteochondral lesions in the knee using a bilayer collagen membrane and bone graft. *J Bone Joint Surg Br.* 2012 Apr;94-B(4):488–92.
107. Hannes Welsch G, Mamisch TC, Zak L, Blanke M, Olk A, Marlovits S, *et al.* Evaluation of Cartilage Repair Tissue after Matrix-Associated Autologous Chondrocyte Transplantation Using a Hyaluronic-Based or a Collagen-Based Scaffold with Morphological MOCART Scoring and Biochemical T2 Mapping: Preliminary Results. *Am J Sports Med.* 2010 May 1;38(5):934–42.
108. Nixon AJ, Rickey E, Butler TJ, Scimeca MS, Moran N, Matthews GL. A chondrocyte infiltrated collagen type I/III membrane (MACI® implant) improves cartilage healing

- in the equine patellofemoral joint model. *Osteoarthritis Cartilage*. 2015 Apr;23(4):648–60.
109. Brittberg M, Slynarski K, editors. *Lower Extremity Joint Preservation: Techniques for Treating the Hip, Knee, and Ankle* [Internet]. Cham: Springer International Publishing; 2021 [cited 2022 May 31]. Available from: <http://link.springer.com/10.1007/978-3-030-57382-9>
110. Cao Z, Dou C, Dong S. Scaffolding Biomaterials for Cartilage Regeneration. *J Nanomater*. 2014 Jul 15;2014:e489128.
111. Jia S, Liu L, Pan W, Meng G, Duan C, Zhang L, *et al*. Oriented cartilage extracellular matrix-derived scaffold for cartilage tissue engineering. *J Biosci Bioeng*. 2012 May 1;113(5):647–53.
112. Moreira Teixeira LS, Leijten JCH, Wennink JWH, Chatterjea AG, Feijen J, van Blitterswijk CA, *et al*. The effect of platelet lysate supplementation of a dextran-based hydrogel on cartilage formation. *Biomaterials*. 2012 May 1;33(14):3651–61.
113. Giannini S, Buda R, Battaglia M, Cavallo M, Ruffilli A, Ramponi L, *et al*. One-step repair in talar osteochondral lesions: 4-year clinical results and t2-mapping capability in outcome prediction. *Am J Sports Med*. 2013 Mar;41(3):511–8.
114. Szychlinska MA, Calabrese G, Ravalli S, Dolcimascolo A, Castrogiovanni P, Fabbi C, *et al*. Evaluation of a Cell-Free Collagen Type I-Based Scaffold for Articular Cartilage Regeneration in an Orthotopic Rat Model. *Materials*. 2020 Jan;13(10):2369.
115. Umeyama R, Yamawaki T, Liu D, Kanazawa S, Takato T, Hoshi K, *et al*. Optimization of culture duration of bone marrow cells before transplantation with a  $\beta$ -tricalcium phosphate/recombinant collagen peptide hybrid scaffold. *Regen Ther*. 2020 Jun 1;14:284–95.
116. Talouki PY, Tackallou SH, Shojaei S, Benisi SZ, Goodarzi V. The role of three-dimensional scaffolds based on polyglycerol sebacate/ polycaprolactone/ gelatin in the presence of Nanohydroxyapatite in promoting chondrogenic differentiation of human adipose-derived mesenchymal stem cells. *Biol Proced Online*. 2023 Mar 24;25(1):9.
117. Toyokawa N, Fujioka H, Kokubu T, Nagura I, Inui A, Sakata R, *et al*. Electrospun Synthetic Polymer Scaffold for Cartilage Repair Without Cultured Cells in an Animal Model. *Arthrosc J Arthrosc Relat Surg*. 2010 Mar 1;26(3):375–83.
118. Liu W, Madry H, Cucchiari M. Application of Alginate Hydrogels for Next-Generation Articular Cartilage Regeneration. *Int J Mol Sci*. 2022 Jan 20;23(3):1147.
119. Sulaiman SB, Idrus RBH, Hwei NM. Gelatin Microsphere for Cartilage Tissue Engineering: Current and Future Strategies. *Polymers*. 2020 Oct 19;12(10):2404.



120. Zhai P, Peng X, Li B, Liu Y, Sun H, Li X. The application of hyaluronic acid in bone regeneration. *Int J Biol Macromol*. 2020 May 15;151:1224–39.
121. Huang C, Dong L, Zhao B, Huang S, Lu Y, Zhang X, *et al*. Tunable Sulfated Alginate-based Hydrogel Platform with enhanced anti-inflammatory and antioxidant capacity for promoting burn wound repair. *J Nanobiotechnology*. 2023 Oct 24;21(1):387.
122. Li G, Shi Z, Zong H, Zhang K, Yan S, Yin J. Injectable, self-healing poly(amino acid)-hydrogel based on phenylboronate ester bond for osteochondral tissue engineering. *Biomed Mater*. 2023 Jul;18(5):055001.
123. Coyle A, Chakraborty A, Huang J, Shamiya Y, Luo W, Paul A. Developing Bioactive Hydrogels Containing Cell-derived Extracellular Matrix: Implications in Drug and Cell-free Bone and Cartilage Repair [Internet]. 2024 [cited 2024 Aug 6]. Available from: <http://biorxiv.org/lookup/doi/10.1101/2024.03.04.583366>
124. Brunello G, Panda S, Schiavon L, Sivolella S, Biasetto L, Del Fabbro M. The Impact of Bioceramic Scaffolds on Bone Regeneration in Preclinical In Vivo Studies: A Systematic Review. *Materials*. 2020 Mar 25;13(7):1500.
125. Deng C, Zhu H, Li J, Feng C, Yao Q, Wang L, *et al*. Bioactive Scaffolds for Regeneration of Cartilage and Subchondral Bone Interface. *Theranostics*. 2018 Feb 15;8(7):1940–55.
126. Kamboj N, Ressler A, Hussainova I. Bioactive Ceramic Scaffolds for Bone Tissue Engineering by Powder Bed Selective Laser Processing: A Review. *Materials*. 2021 Sep 16;14(18):5338.
127. Bernstein A, Niemeyer P, Salzmann G, Südkamp NP, Hube R, Klehm J, *et al*. Microporous calcium phosphate ceramics as tissue engineering scaffolds for the repair of osteochondral defects: Histological results. *Acta Biomater*. 2013 Jul 1;9(7):7490–505.
128. Cai H, Yao Y, Xu Y, Wang Q, Zou W, Liang J, *et al*. A Col I and BCP ceramic bi-layer scaffold implant promotes regeneration in osteochondral defects. *RSC Adv*. 2019;9(7):3740–8.
129. Cao Y, Cheng P, Sang S, Xiang C, An Y, Wei X, *et al*. 3D printed PCL/GelMA biphasic scaffold boosts cartilage regeneration using co-culture of mesenchymal stem cells and chondrocytes: In vivo study. *Mater Des*. 2021 Nov 15;210:110065.
130. Seol YJ, Park JY, Jeong W, Kim TH, Kim SY, Cho DW. Development of hybrid scaffolds using ceramic and hydrogel for articular cartilage tissue regeneration. *J Biomed Mater Res A*. 2015 Apr;103(4):1404–13.

131. Wasylęczko M, Sikorska W, Chwojnowski A. Review of Synthetic and Hybrid Scaffolds in Cartilage Tissue Engineering. *Membranes*. 2020 Nov 17;10(11):348.
132. Benders KEM, van Weeren PR, Badylak SF, Saris DBF, Dhert WJA, Malda J. Extracellular matrix scaffolds for cartilage and bone regeneration. *Trends Biotechnol*. 2013 Mar;31(3):169–76.
133. Das P, Singh YP, Joardar SN, Biswas BK, Bhattacharya R, Nandi SK, *et al*. Decellularized Caprine Conchal Cartilage toward Repair and Regeneration of Damaged Cartilage. *ACS Appl Bio Mater*. 2019 May 20;2(5):2037–49.
134. Das P, Mishra R, Devi B, Rajesh K, Basak P, Roy M, *et al*. Decellularized xenogenic cartilage extracellular matrix (ECM) scaffolds for the reconstruction of osteochondral defects in rabbits. *J Mater Chem B*. 2021 Jun 23;9(24):4873–94.
135. G T, S J, J L, F W, X L, Y D, *et al*. Cell-free decellularized cartilage extracellular matrix scaffolds combined with interleukin 4 promote osteochondral repair through immunomodulatory macrophages: In vitro and *in vivo* preclinical study. *Acta Biomater* [Internet]. 2021 Jun [cited 2023 Jun 26];127. Available from: <https://pubmed.ncbi.nlm.nih.gov/33812074/>
136. Zhang Q, Hu Y, Long X, Hu L, Wu Y, Wu J, *et al*. Preparation and Application of Decellularized ECM-Based Biological Scaffolds for Articular Cartilage Repair: A Review. *Front Bioeng Biotechnol* [Internet]. 2022 [cited 2023 Jun 26];10. Available from: <https://www.frontiersin.org/articles/10.3389/fbioe.2022.908082>
137. Doyle SE, Snow F, Duchi S, O’Connell CD, Onofrillo C, Di Bella C, *et al*. 3D Printed Multiphasic Scaffolds for Osteochondral Repair: Challenges and Opportunities. *Int J Mol Sci*. 2021 Nov 17;22(22):12420.
138. Holmes B, Zhu W, Li J, Lee JD, Zhang LG. Development of Novel Three-Dimensional Printed Scaffolds for Osteochondral Regeneration. *Tissue Eng Part A*. 2015 Jan 1;21(1–2):403–15.
139. Sutherland A, Beck E, Dennis S, Converse G, Hopkins R, Berkland C, *et al*. Decellularized Cartilage May Be a Chondroinductive Material for Osteochondral Tissue Engineering. *PLOS ONE*. 2015 May 12;10:e0121966.
140. Kim YS, Majid M, Melchiorri AJ, Mikos AG. Applications of decellularized extracellular matrix in bone and cartilage tissue engineering. *Bioeng Transl Med*. 2018 Oct 26;4(1):83–95.
141. Tian G, Jiang S, Li J, Wei F, Li X, Ding Y, *et al*. Cell-free decellularized cartilage extracellular matrix scaffolds combined with interleukin 4 promote osteochondral

- repair through immunomodulatory macrophages: In vitro and *in vivo* preclinical study. *Acta Biomater.* 2021 Jun 1;127:131–45.
142. Kim M, Farrell MJ, Steinberg DR, Burdick JA, Mauck RL. Enhanced nutrient transport improves the depth-dependent properties of tri-layered engineered cartilage constructs with zonal co-culture of chondrocytes and MSCs. *Acta Biomater.* 2017 Aug;58:1–11.
143. Sartori M, Pagani S, Ferrari A, Costa V, Carina V, Figallo E, *et al.* A new bi-layered scaffold for osteochondral tissue regeneration: In vitro and *in vivo* preclinical investigations. *Mater Sci Eng C Mater Biol Appl.* 2017 Jan 1;70(Pt 1):101–11.
144. Longley R, Ferreira AM, Gentile P. Recent Approaches to the Manufacturing of Biomimetic Multi-Phasic Scaffolds for Osteochondral Regeneration. *Int J Mol Sci.* 2018 Jun 13;19(6):1755.
145. Liu K, Liu Y, Duan Z, Ma X, Fan D. A biomimetic bi-layered tissue engineering scaffolds for osteochondral defects repair. *Sci China Technol Sci.* 2021 Apr 1;64(4):793–805.
146. Fu L, Yang Z, Gao C, Li H, Yuan Z, Wang F, *et al.* Advances and prospects in biomimetic multilayered scaffolds for articular cartilage regeneration. *Regen Biomater.* 2020 Dec 17;7(6):527–42.
147. Wang W, Li H, Song P, Guo Y, Luo D, Li H, *et al.* Photo-crosslinked integrated triphasic scaffolds with gradient composition and strength for osteochondral regeneration. *J Mater Chem B.* 2024 Jan 31;12(5):1271–84.
148. Yu X, Deng Z, Li H, Ma Y, Ma X, Zheng Q. Anisotropic hydrogel fabricated by controlled diffusion as a bio-scaffold for the regeneration of cartilage injury. *RSC Adv.* 2022 Sep 28;12(43):28254–63.
149. Molley TG, Hung T tyng, Kilian KA. Cell-Laden Gradient Microgel Suspensions for Spatial Control of Differentiation During Biofabrication. *Adv Healthc Mater.* 2022;11(24):2201122.
150. Weigel N, Grigoryev E, Fertala N, Thiele J. Fabrication of Thermoresponsive and Multimaterial Hydrogel Sheets by Spatially Controlled Aspiration and Interconnection of Microgel Building Blocks. *Adv Mater Technol.* 2023;8(23):2300374.
151. Camacho P, Behre A, Fainor M, Seims KB, Chow LW. Spatial organization of biochemical cues in 3D-printed scaffolds to guide osteochondral tissue engineering. *Biomater Sci.* 2021 Oct 12;9(20):6813–29.
152. Chukaew S, Parivatphun T, Thonglam J, Khangkhamano M, Meesane J, Kokoo R. Biphasic scaffolds of polyvinyl alcohol/gelatin reinforced with polycaprolactone as biomedical materials supporting for bone augmentation based on anatomical

- mimicking; fabrication, characterization, physical and mechanical properties, and *in vitro* testing. *J Mech Behav Biomed Mater.* 2023 Jul 1;143:105933.
153. Kilian D, Ahlfeld T, Akkineni AR, Bernhardt A, Gelinsky M, Lode A. 3D Bioprinting of osteochondral tissue substitutes – *in vitro*-chondrogenesis in multi-layered mineralized constructs. *Sci Rep.* 2020 May 19;10(1):1–17.
  154. Pugliese R, Graziosi S. Biomimetic scaffolds using triply periodic minimal surface-based porous structures for biomedical applications. *SLAS Technol.* 2023 Jun 1;28(3):165–82.
  155. Cianflone E, Brouillet F, Grossin D, Soulié J, Josse C, Vig S, *et al.* Toward Smart Biomimetic Apatite-Based Bone Scaffolds with Spatially Controlled Ion Substitutions. *Nanomaterials.* 2023 Jan;13(3):519.
  156. Gao Y, Zhang X, Zhou H. Biomimetic Hydrogel Applications and Challenges in Bone, Cartilage, and Nerve Repair. *Pharmaceutics.* 2023 Oct;15(10):2405.
  157. Rosellini E, Giordano C, Guidi L, Cascone MG. Biomimetic Approaches in Scaffold-Based Blood Vessel Tissue Engineering. *Biomimetics.* 2024 Jul;9(7):377.
  158. Kim SH, Kim SH, Jung Y. TGF- $\beta$ 3 encapsulated PLCL scaffold by a supercritical CO<sub>2</sub>-HFIP co-solvent system for cartilage tissue engineering. *J Controlled Release.* 2015 May 28;206:101–7.
  159. Zhang Y, Tang CL, Chen WJ, Zhang Q, Wang SL. Dynamic compression combined with exogenous SOX-9 promotes chondrogenesis of adipose-derived mesenchymal stem cells in PLGA scaffold. *Eur Rev Med Pharmacol Sci.* 2015;19(14):2671–8.
  160. Wang T, Lai JH, Han LH, Tong X, Yang F. Modulating stem cell–chondrocyte interactions for cartilage repair using combinatorial extracellular matrix-containing hydrogels. *J Mater Chem B.* 2016 Nov 30;4(47):7641–50.
  161. Wu Y, Yang Z, Denslin V, Ren X, Lee CS, Yap FL, *et al.* Repair of Osteochondral Defects With Predifferentiated Mesenchymal Stem Cells of Distinct Phenotypic Character Derived From a Nanotopographic Platform. *Am J Sports Med.* 2020 Jun;48(7):1735–47.
  162. Kotobuki N, Hirose M, Takakura Y, Ohgushi H. Cultured Autologous Human Cells for Hard Tissue Regeneration: Preparation and Characterization of Mesenchymal Stem Cells from Bone Marrow. *Artif Organs.* 2004;28(1):33–9.
  163. Lodi D, Iannitti T, Palmieri B. Stem cells in clinical practice: applications and warnings. *J Exp Clin Cancer Res CR.* 2011 Jan 17;30:9.
  164. Hernigou P, Bouthors C, Bastard C, Flouzat Lachaniette CH, Rouard H, Dubory A. Subchondral bone or intra-articular injection of bone marrow concentrate

- mesenchymal stem cells in bilateral knee osteoarthritis: what better postpone knee arthroplasty at fifteen years? A randomized study. *Int Orthop*. 2021 Feb 1;45(2):391–9.
165. Xue R, Chung B, Tamaddon M, Carr J, Liu C, Cartmell SH. Osteochondral tissue coculture: An *in vitro* and *in silico* approach. *Biotechnol Bioeng*. 2019 Nov;116(11):3112–23.
166. Gruenloh W, Kambal A, Sondergaard C, McGee J, Nacey C, Kalomoiris S, *et al*. Characterization and In Vivo Testing of Mesenchymal Stem Cells Derived from Human Embryonic Stem Cells. *Tissue Eng Part A*. 2011 Jun;17(11–12):1517–25.
167. Yasui Y, Chijimatsu R, Hart DA, Koizumi K, Sugita N, Shimomura K, *et al*. Preparation of Scaffold-Free Tissue-Engineered Constructs Derived from Human Synovial Mesenchymal Stem Cells Under Low Oxygen Tension Enhances Their Chondrogenic Differentiation Capacity. *Tissue Eng Part A*. 2016 Mar;22(5–6):490–500.
168. Fu L, Li P, Li H, Gao C, Yang Z, Zhao T, *et al*. The Application of Bioreactors for Cartilage Tissue Engineering: Advances, Limitations, and Future Perspectives. *Stem Cells Int*. 2021;2021:6621806.
169. Wei W, Dai H. Articular cartilage and osteochondral tissue engineering techniques: Recent advances and challenges. *Bioact Mater*. 2021 Dec;6(12):4830–55.
170. Robey TE, Saiget MK, Reinecke H, Murry CE. Systems approaches to preventing transplanted cell death in cardiac repair. *J Mol Cell Cardiol*. 2008 Oct;45(4):567–81.
171. Zhang M, Methot D, Poppa V, Fujio Y, Walsh K, Murry CE. Cardiomyocyte Grafting for Cardiac Repair: Graft Cell Death and Anti-Death Strategies. *J Mol Cell Cardiol*. 2001 May;33(5):907–21.
172. Michel JB. Ano k is in the Cardiovascular System. *Arterioscler Thromb Vasc Biol*. 2003 Dec;23(12):2146–54.
173. Taddei ML, Giannoni E, Fiaschi T, Chiarugi P. Anoikis: an emerging hallmark in health and diseases. *J Pathol*. 2012 Jan;226(2):380–93.
174. Lee S, Choi E, Cha MJ, Hwang KC. Cell adhesion and long-term survival of transplanted mesenchymal stem cells: a prerequisite for cell therapy. *Oxid Med Cell Longev*. 2015;2015:632902.
175. Aswathy J, Resmi R, Joseph J, Joseph R, John A, Abraham A. Calotropis gigantea incorporated alginate dialdehyde-gelatin hydrogels for cartilage tissue regeneration in Osteoarthritis. *J Drug Deliv Sci Technol*. 2023 Apr 1;82:104372.

176. Branam GM, Saber AY. Osteochondral Autograft Transplantation [Internet]. StatPearls [Internet]. StatPearls Publishing; 2022 [cited 2023 Feb 8]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK560655/>
177. Frank RM, Cotter EJ, Lee S, Poland S, Cole BJ. Do Outcomes of Osteochondral Allograft Transplantation Differ Based on Age and Sex? A Comparative Matched Group Analysis. *Am J Sports Med.* 2018 Jan;46(1):181–91.
178. Ayala Mejias JD, Sciamanna RCA, Muniesa MPE, Pérez-España LA. A case report of semitendinosus tendon autograft for reconstruction of the meniscal wall supporting a collagen implant. *BMC Sports Sci Med Rehabil.* 2013 Mar 28;5:4.
179. Johnson LL, Feagin JA. Autogenous tendon graft substitution for absent knee joint meniscus: a pilot study. *Arthrosc J Arthrosc Relat Surg Off Publ Arthrosc Assoc N Am Int Arthrosc Assoc.* 2000 Mar;16(2):191–6.
180. Kohn D. Autograft meniscus replacement: experimental and clinical results. *Knee Surg Sports Traumatol Arthrosc Off J ESSKA.* 1993;1(2):123–5.
181. Bedi A, Feeley BT, Williams RJ. Management of articular cartilage defects of the knee. *J Bone Joint Surg Am.* 2010 Apr;92(4):994–1009.
182. Desando G, Cavallo C, Sartoni F, Martini L, Parrilli A, Veronesi F, *et al.* Intra-articular delivery of adipose derived stromal cells attenuates osteoarthritis progression in an experimental rabbit model. *Arthritis Res Ther.* 2013 Jan 29;15(1):R22.
183. Dragoo JL, Samimi B, Zhu M, Hame SL, Thomas BJ, Lieberman JR, *et al.* Tissue-engineered cartilage and bone using stem cells from human infrapatellar fat pads. *J Bone Joint Surg Br.* 2003 Jul;85(5):740–7.
184. English A, Jones EA, Corscadden D, Henshaw K, Chapman T, Emery P, *et al.* A comparative assessment of cartilage and joint fat pad as a potential source of cells for autologous therapy development in knee osteoarthritis. *Rheumatol Oxf Engl.* 2007 Nov;46(11):1676–83.
185. Giavaresi G, Bondioli E, Melandri D, Giardino R, Tschon M, Torricelli P, *et al.* Response of human chondrocytes and mesenchymal stromal cells to a decellularized human dermis. *BMC Musculoskelet Disord.* 2013 Jan 7;14:12.
186. Knutsen G, Engebretsen L, Ludvigsen TC, Drogset JO, Grøntvedt T, Solheim E, *et al.* Autologous chondrocyte implantation compared with microfracture in the knee. A randomized trial. *J Bone Joint Surg Am.* 2004 Mar;86(3):455–64.
187. Koh YG, Jo SB, Kwon OR, Suh DS, Lee SW, Park SH, *et al.* Mesenchymal stem cell injections improve symptoms of knee osteoarthritis. *Arthrosc J Arthrosc Relat Surg Off Publ Arthrosc Assoc N Am Int Arthrosc Assoc.* 2013 Apr;29(4):748–55.

188. Koh YG, Choi YJ. Infrapatellar fat pad-derived mesenchymal stem cell therapy for knee osteoarthritis. *The Knee*. 2012 Dec;19(6):902–7.
189. Ma A, Jiang L, Song L, Hu Y, Dun H, Daloz P, *et al.* Reconstruction of cartilage with clonal mesenchymal stem cell-acellular dermal matrix in cartilage defect model in nonhuman primates. *Int Immunopharmacol*. 2013 Jul;16(3):399–408.
190. Brittberg M, Peterson L, Sjögren-Jansson E, Tallheden T, Lindahl A. Articular cartilage engineering with autologous chondrocyte transplantation. A review of recent developments. *J Bone Joint Surg Am*. 2003;85-A Suppl 3:109–15.
191. Massen FK, Inauen CR, Harder LP, Runer A, Preiss S, Salzmann GM. One-Step Autologous Minced Cartilage Procedure for the Treatment of Knee Joint Chondral and Osteochondral Lesions: A Series of 27 Patients With 2-Year Follow-up. *Orthop J Sports Med*. 2019 Jun;7(6):2325967119853773.
192. Na Y, Shi Y, Liu W, Jia Y, Kong L, Zhang T, *et al.* Is implantation of autologous chondrocytes superior to microfracture for articular-cartilage defects of the knee? A systematic review of 5-year follow-up data. *Int J Surg Lond Engl*. 2019 Aug;68:56–62.
193. de Windt TS, Vonk LA, Slaper-Cortenbach ICM, Nizak R, van Rijen MHP, Saris DBF. Allogeneic MSCs and Recycled Autologous Chondrons Mixed in a One-Stage Cartilage Cell Transplantation: A First-in-Man Trial in 35 Patients. *Stem Cells Dayt Ohio*. 2017 Aug;35(8):1984–93.
194. Korpershoek JV, Vonk LA, Kester EC, Creemers LB, de Windt TS, Kip MMA, *et al.* Efficacy of one-stage cartilage repair using allogeneic mesenchymal stromal cells and autologous chondron transplantation (IMPACT) compared to nonsurgical treatment for focal articular cartilage lesions of the knee: study protocol for a crossover randomized controlled trial. *Trials*. 2020 Oct 9;21(1):842.
195. Saris TFF, de Windt TS, Kester EC, Vonk LA, Custers RJH, Saris DBF. Five-Year Outcome of 1-Stage Cell-Based Cartilage Repair Using Recycled Autologous Chondrons and Allogenic Mesenchymal Stromal Cells: A First-in-Human Clinical Trial. *Am J Sports Med*. 2021 Mar;49(4):941–7.
196. Garc á-G ómez I, Elvira G, Zapata AG, Lamana ML, Ram íez M, Castro JG, *et al.* Mesenchymal stem cells: biological properties and clinical applications. *Expert Opin Biol Ther*. 2010 Oct;10(10):1453–68.
197. Wakitani S, Imoto K, Yamamoto T, Saito M, Murata N, Yoneda M. Human autologous culture expanded bone marrow mesenchymal cell transplantation for repair of cartilage defects in osteoarthritic knees. *Osteoarthritis Cartilage*. 2002 Mar;10(3):199–206.

198. Bekkers JEJ, Creemers LB, Tsuchida AI, van Rijen MHP, Custers RJH, Dhert WJA, *et al.* One-stage focal cartilage defect treatment with bone marrow mononuclear cells and chondrocytes leads to better macroscopic cartilage regeneration compared to microfracture in goats. *Osteoarthritis Cartilage*. 2013 Jul;21(7):950–6.
199. Bekkers JEJ, Tsuchida AI, van Rijen MHP, Vonk LA, Dhert WJA, Creemers LB, *et al.* Single-stage cell-based cartilage regeneration using a combination of chondrons and mesenchymal stromal cells: comparison with microfracture. *Am J Sports Med*. 2013 Sep;41(9):2158–66.
200. Vonk LA, Doulabi BZ, Huang C, Helder MN, Everts V, Bank RA. Preservation of the chondrocyte's pericellular matrix improves cell-induced cartilage formation. *J Cell Biochem*. 2010 May;110(1):260–71.
201. Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, *et al.* Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. *Arthritis Rheum*. 1986 Aug;29(8):1039–49.
202. Attur MG, Patel IR, Patel RN, Abramson SB, Amin AR. Autocrine production of IL-1 beta by human osteoarthritis-affected cartilage and differential regulation of endogenous nitric oxide, IL-6, prostaglandin E2, and IL-8. *Proc Assoc Am Physicians*. 1998 Feb;110(1):65–72.
203. Radin EL, Ehrlich MG, Chernack R, Abernethy P, Paul IL, Rose RM. Effect of repetitive impulsive loading on the knee joints of rabbits. *Clin Orthop*. 1978 Mar 1;(131):288–93.
204. Wang X, Wu Q, Zhang R, Fan Z, Li W, Mao R, *et al.* Stage-specific and location-specific cartilage calcification in osteoarthritis development. *Ann Rheum Dis*. 2023 Mar;82(3):393–402.